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ABSTRACT 
 
Very few cancer patients are cured through drug therapy alone, with the majority 
exhibiting acquired resistance.  To date, most studies of therapeutic escape have 
focused upon tumor-intrinsic mechanisms of drug resistance with little attention paid to 
the role of normal host cells in preventing complete tumor eradication. In the present 
study we implicate co-operative bi-directional signaling between melanoma cells and 
fibroblasts in the generation of a pro-survival niche that mediates drug resistance.  
Mass-spectrometry based phosphoproteomics was used to show that BRAF inhibition 
and chemotherapy drugs enhanced the survival of both melanoma cells and fibroblasts 
through the induction of fibronectin (FN)/integrin α5β1 signaling. Immunohistochemical 
staining confirmed the induction of FN in mouse xenografts and human melanoma 
specimens following BRAF inhibitor treatment.  Adhesion to FN amplified the adaptive 
EGFR, HER3 and c-MET receptor tyrosine kinase (RTK) signals required for 
PI3K/AKT/Mcl-1-mediated melanoma cell survival when BRAF was inhibited. At the 
same time, BRAF inhibition led, directly and indirectly, to the paracrine release of HGF 
and neuregulin from fibroblasts, with TGF-β release from the melanoma cells increasing 
both fibroblast differentiation and survival. Although dual inhibition of RTKs and BRAF 
did not reverse host-mediated resistance, therapeutic escape was overcome through 
combined BRAF/PI3K inhibition, suggesting the PI3K/AKT pathway to be a common 
signaling vulnerability in microenvironment-mediated drug resistance. Our work 
suggests that durable responses to targeted therapies will only be achieved through 
 ix 
dual targeting of the tumor and the adaptive host responses to therapy. These findings 
are especially important for a cancer such as melanoma, where as few as one cell can 
repopulate the entire tumor in vivo. 
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CHAPTER I: 
INTRODUCTION1 
 
Skin malignancies and melanoma 
Skin cancer is the most prevalent malignancy in the United States, with over 3.5 million 
new cancers diagnosed in 2 million people every year1. The incidence and mortality of 
skin cancer is steadily increasing2. One in every 5 Americans will be diagnosed with 
skin cancer in their lifetime3. The most common types of skin malignancy are basal cell 
carcinoma, squamous cell carcinoma and melanoma. Although melanoma is a relatively 
rare malignancy, accounting for less than 5% of all skin cancers, it is responsible for the 
majority of skin cancer-related deaths 3,4. Approximately 76,100 new cases of 
melanoma are expected to be diagnosed in 2014 4. Whereas overall rates of cancer 
death continue to decrease, risk of death from melanoma continues to rise year on year 
and showed a 7% increase during the period 1990-2006 5. Skin color is the predominant 
constitutional risk factor for skin cancer of any type 2. 
Melanoma arises from malignantly transformed melanocytes, in most cases from 
normal skin rather than a preexisting nevus 2,6. This malignancy occurs in several 
morphologic subtypes, divided into those with rapid radial growth, such as superficial  
spreading melanoma, lentigo maligna, and acral lentiginous melanoma, and lesions with  
 
1	  Some	  parts	  of	  this	  dissertation	  have	  been	  published	  previously;	  see	  appendix	  D	  for	  copyright	  permission.	  Portions	  of	  this	  dissertation	  are	  also	  in	  the	  process	  of	  being	  prepared	  for	  publication.	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relative absence of radial growth, such as nodular melanoma 3. The individual subtypes 
of melanoma correlate differently to sun exposure, with some strongly correlated to a 
history of exposure to sunlight (lentigo maligna) and others occurring in areas 
completely protected from sun exposure (acral lentiginous melanoma) 3. Vertical growth 
of melanoma can be a good indicator of prognosis and is typically measured in terms of 
Breslow thickness 3,7. Breslow thickness of a melanoma is determined by measuring the 
distance from the epidermal basement membrane to the deepest melanoma tumor cells 
3. Besides Breslow thickness, other prognostic factors include ulceration, lymph node 
involvement, site of primary melanoma, age of patient and gender of patient 3,8. These 
factors can affect the staging of melanoma, which involves assessment of the primary 
tumor, the regional lymph nodes and distant metastatic melanoma 9.  
 
Melanoma genotypes  
DNA damage due to ultraviolet radiation is the leading cause of mutations found in 
melanoma 10. The technology and techniques developed during completion of the 
Human Genome Project has had a tremendous impact on the advancement of therapy 
for metastatic melanoma. Large-scale DNA studies enabled the discovery of a number 
of high-frequency oncogenic mutations in melanoma 11. Approximately half of all 
cutaneous melanomas harbor a mutation in the BRAF gene leading to constitutive 
activity of the resulting kinase, driving cell growth, survival and motility 12-14. Although 
much attention has been focused on BRAF-mutant melanomas recently, the first 
oncogene identified in melanoma was actually NRAS in 1984 15. Today it is known that 
mutations in NRAS occur in 22% of all human melanomas, where as mutations in 
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KRAS, and HRAS are quite rare and have only been detected in 1-2% of patients 16. 
NRAS- and BRAF-mutant melanomas differ from each other in the clinical presentation 
and prognostic characteristics. One large histopathological study has shown that, unlike 
NRAS-mutant melanomas, melanomas driven by oncogenic BRAF tended to produce 
larger, rounded and highly pigmented tumors with a propensity for upward migration 
and nest formation 17,18. NRAS-mutant melanoma tumors typically present in patients 
who are older, with a history of chronic UV exposure 17. In these patients, the primary 
melanomas tend to be thicker, have higher rates of mitosis, and are frequently located 
on the extremities 18. While ulceration is more common in BRAF-mutant than NRAS-
mutant melanomas, the occurrence of an NRAS mutation is linked to shorter 
melanoma-specific survival 18. Approximately 5-12% of all melanomas are predicted to 
be hereditary, 40% of which are linked to mutations in CDKN2A 19-21. 
 
The role of mutated BRAF in melanoma development and progression 
The identification of activating mutations in BRAF in ~50% of all cutaneous melanomas 
in 2002 was a landmark event in the understanding of melanoma biology 22. Raf 
(RApidly growing Fibrosarcoma) proteins constitute a 3-member family of 
Serine/Threonine kinases (ARAF, BRAF and CRAF) with closely overlapping functions 
that constitute part of the Ras/Raf/MEK/ERK mitogen activated protein kinase (MAPK) 
signal transduction cascade. Although >50 mutations in BRAF have now been 
described, the most common BRAF mutation in melanoma, accounting for 80% of all of 
the BRAF mutations, is a valine to glutamic acid (V600E) substitution 22,23.  Acquisition 
of a V600E mutation in BRAF destabilizes the inactive kinase conformation switching 
 4 
the equilibrium towards the active form, leading to constitutive activity 23. Other BRAF 
mutations identified from melanoma specimens are the V600K and V600D/V600R 
variants, which account for 16% and 3% of all BRAF mutations, respectively 24. A minor 
sub-group of melanomas were also identified with BRAF mutations in positions other 
than 600 25. These non-V600 position BRAF mutants differ from the position-600 
mutants, show impaired intrinsic BRAF kinase activity and require the presence of 
CRAF to transactivate their MAPK signaling 23. Analysis of a large panel of melanoma 
cell lines and tissues revealed that ~1% of melanoma cell lines had either D594G or 
G469E mutation in BRAF, respectively and that 1% of melanoma specimens harbored a 
G469A mutation in BRAF 25. Approximately 15-20% of melanomas harbor activating 
Ras mutations and a small percentage are c-KIT mutant. The initiating oncogenic event 
in the remaining 30-35% of BRAF wild-type melanoma is currently unknown. 
There is now a wealth of evidence demonstrating that mutated BRAF is a bona fide 
melanoma oncogene. Mechanistically, mutated BRAF exerts most of its oncogenic 
effects through the activation of the MAPK pathway 26. MAPK activity drives the 
uncontrolled growth of melanoma cells by upregulating the expression of cyclin D1 and 
through the suppression of the cyclin dependent kinase inhibitor p27KIP1. Pre-clinical 
studies have shown that introduction of mutated BRAF into immortalized melanocytes 
leads to anchorage-independent growth and tumor formation in immunocompromised 
mice 26. Conversely, downregulation of mutated BRAF using RNAi causes cell cycle 
arrest and apoptosis in both in vitro and in vivo BRAF V600E mutant melanoma models 
26. Although it has been suggested that the acquisition of the BRAF V600E mutation is 
an early event in melanoma development, with 80% of all benign nevi shown to be 
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BRAF mutant, the available evidence indicates that mutant BRAF alone cannot initiate 
melanoma 27,28. The introduction of V600E mutated BRAF into primary human 
melanocytes does not lead to oncogenic transformation and is instead associated with 
the onset of senescence 28. Likewise, an immunohistochemical analysis of a large 
cohort of melanocytic nevi revealed positive staining for senescence associated beta 
galactosidase as well as histological markers of growth arrest 28.  
Instead, melanoma development seems to require both BRAF/MAPK and phospho-
inositide 3-kinase (PI3K)/AKT pathway activity. In BRAF mutant melanoma cells, this 
can arise through the loss of expression or functional inactivation of the tumor 
suppressor phosphatase and tensin homolog (PTEN) which is lost in 10-30% of 
melanoma cell lines and 10% of human tumor material 29,30. Activation of AKT signaling 
in BRAF mutant melanoma also occurs as the result of increased AKT3 expression and 
also rarely through the acquisition of activating E17K mutations in AKT3 26. The 
requirement for both mutant BRAF and activation of the PI3K/AKT signaling pathway in 
melanoma initiation and progression is supported by transgenic mouse studies showing 
that introduction of the BRAF-V600E mutation in concert with the suppression of PTEN 
expression is required for full melanoma development 31.  
In addition to its well-characterized effects upon growth, there is emerging evidence that 
aberrant BRAF signaling also regulates the survival of melanoma cells (Figure 1). A 
number of studies have shown that siRNA knockdown of BRAF and small molecule 
BRAF inhibitors induce apoptosis in BRAF V600E mutant melanoma cells through the 
regulation of the pro-apoptotic proteins BIM, BMF, BAD and Mcl-1 32-35. The best 
studied of these molecules is the BH3-only protein BIM which exerts its cytotoxic activity 
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by binding to and antagonizing the anti-apoptotic proteins Bcl-2, Bcl-w, Bcl-XL and Mcl-
1 36,37. Expression of BIM is regulated both transcriptionally and post-transcriptionally by 
a number of signaling pathways, including BRAF/MEK/ERK, JNK, p38 MAPK and 
PI3K/AKT 38. BIM exists as three isoforms BIM-EL (extra long), BIM-L (long) and BIM-S 
(short) that are generated by alternate splicing. Of the three splice forms BIM-S is 
thought to be the most important for apoptosis induction. It is known that the BRAF 
V600E mutation regulates BIM expression through the MEK/ERK pathway-mediated 
phosphorylation of the extra-long form of BIM (BIM-EL) at Serine 69, leading to its 
subsequent degradation by the proteasome 32,39. Inhibition of BRAF also regulates BIM 
splicing and leads to the selective upregulation of BIM-S expression 40. The essential 
role of the BIM-S splice form for BRAF inhibitor mediated apoptosis was demonstrated 
by the siRNA knockdown of BIM-S and the fact that the introduction of BRAF V600E 
into BRAF wild-type melanoma cells and melanocytes downregulated basal levels of 
BIM-S expression 40. In these instances, the increase in BIM-S expression observed 
was associated with an upregulation of the splicing factor SRp55 40. 
Malignantly transformed cells are highly invasive and there is good evidence that 
oncogenic BRAF plays a key role in this process (Figure 2). Early studies, that predated 
the discovery of BRAF mutations, showed constitutive MAPK signaling activity to drive 
the invasion of melanoma cells through the increased expression of the pro-migratory 
β3 integrin receptor and the upregulation of matrix metalloproteinase (MMP) expression 
41. It has since been shown that activation of the BRAF/MEK/ERK pathway aids the 
motile phenotype of melanoma through reorganization of the cytoskeleton. Two recent 
studies demonstrated a role for mutant BRAF in regulating the expression of 
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RND3/RhoE/Rho8, a regulator of the crosstalk between the BRAF/MEK/ERK and 
Rho/Rock/LIM kinase/Cofilin pathways 42. Silencing of BRAF using siRNA or inhibition 
of MEK downregulated RND3 expression, which in turn increased stress fiber formation 
and enhanced focal adhesion stability. Depletion of RND3 by siRNA was found to 
prevent the invasion of melanoma cells in a 3D collagen implanted spheroid cell culture 
model 42.  
Other recent work showed mutated BRAF to induce the invasion of melanoma cells 
through a novel pathway involving the release of cytosolic calcium 14. This discovery 
came from a microarray screen that identified the cyclic GMP phosphodiesterase 
PDE5A as a novel gene that was downregulated by oncogenic BRAF. Although the re-
introduction of PDE5A did not confer a growth advantage to BRAF V600E melanoma 
cells it did significantly suppress cell invasion 14. A mechanistic analysis showed that 
downregulation of PDE5A by mutant BRAF increased levels of intracellular cGMP 
leading to cytosolic calcium release. The increased intracellular calcium then led to 
phosphorylation of myosin light chain 2 (MLC2), which enhanced cell contractility and 
led to an increase in the invasive capacity. Of clinical relevance, the authors observed 
that a number of commonly used PDE inhibitors such as sildenafil (more commonly 
known as Viagra) and tadalafil blocked the activity of PDE5A and enhanced the 
contractility and invasion of the melanoma cells 14. It was suggested that the use of 
these PDE inhibitors could be deleterious in patients with BRAF mutant melanoma. 
In addition to the direct effects upon melanoma cell behavior described above, the 
presence of a BRAF mutation also regulates the interaction of melanoma cells and the 
host microenvironment, in particular by allowing the tumor cells to escape immune 
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surveillance. Inhibition of BRAF/MAPK signaling in BRAF V600E mutant melanoma 
cells is known to reduce the release of immunosuppressive cytokines and reverses the 
suppressive effects of melanoma cell culture supernatants upon dendritic cell activation 
43. There is also evidence that the presence of a BRAF mutation allows melanoma cells 
to escape T-cell recognition. Others have shown that increased BRAF/MEK/ERK 
signaling suppresses the expression of highly immunogenic differentiation antigens from 
melanoma cell lines 44,45. These effects were noted to be dependent upon continuous 
BRAF/MAPK signaling and the expression of the pigmentations antigens could be 
restored following the inhibition of either BRAF or MEK. There seemed to be some 
benefit of inhibiting the MAPK pathway using BRAF rather than MEK inhibitors, with 
BRAF inhibition shown to restore the antigen specific function of T-cells, whereas MEK 
inhibition actually suppressed T-cell activity 45. Given the current interest in combining 
BRAF and MEK inhibitors with immunotherapies such as ipilimumab, these results may 
also be of clinical relevance.  
 
Therapeutic strategies 
As with many other types of cancers, early detection is key in the treatment of 
melanoma, with early-stage patients having the most favorable prognosis 6. While 
cytotoxic chemotherapies have been shown to be effective in a number of cancers, for 
over 40 years the melanoma community suffered from infrequent responses to these 
therapeutic approaches 11. For many years disseminated melanoma was assumed to be 
resistant to all forms of therapeutic intervention. 
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William Norris, a general practitioner in London, first described melanoma and its 
clinical, genetic and epidemiological characteristics in the 1820s 11,46. The early years of 
melanoma treatment were defined by the development of advanced surgical 
techniques. Even in the early years of melanoma diagnosis and treatment, people 
realized that once the melanoma has disseminated, surgical and systemic treatments 
were largely futile 11,47. While early-stage melanomas have greatly benefited from 
improved surgical techniques, the effort to develop effective therapies for advanced 
melanomas has encountered slow progress. Present day, early-stage melanomas 
exhibit 80-90% 20-year survival following surgical intervention and can therefore be 
considered curable through surgery alone 11. Meanwhile, only a small number of agents 
obtained FDA approval for the treatment of advanced melanoma between 1970 and 
2000, including dacarbazine in 1975, high-dose interferon alpha 2b in 1995, and high-
dose interkeukin 2 in 1998 11. Although the approval of these agents had marked a new 
era for systemic treatment of disseminated melanoma, the agents were usually 
associated with poor or rare responses and high toxicities. Dacarbazine treatment was 
associated with only partial responses and a 1 year overall survival of 27% 48. In a 
randomized Phase III trial of IFN alpha-2b versus observation, high-risk resected 
patients benefited from an increase in median disease-free survival from 1 to 1.7 years 
and overall survival from 2.8 to 3.8 years, however the majority of patients required 
dose adjustment due to high toxicity levels 49. Meanwhile, high-dose interleukin-2 (IL-2) 
treatment was associated with a number of durable complete responses but these were 
quite rare, occurring in only 6% of patients 50. By 2003, several clinical trials have been 
carried out focusing on immunotherapies for treatment of advanced melanoma, 
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however due to minimal efficacy in prolonging survival or blocking recurrence, good 
surgical management remained the standard of care 51. 
By 2008, the 20-year survival for patients with stage I melanoma was nearly 90%, for 
patients with stage II it was 50%, for patients with stage III it was 40% and for patients 
with stage IV disease it was 10% 52. John Kirkwood and colleagues analyzed the 
historical meta-data for 42 phase II clinical trials in order to develop a point of reference 
for future trials and found that median survival for metastatic disease was 6.2 months, 
with a 1-year overall survival rate of 25.5% 53. With recent developments in 
understanding of the molecular biology underlying advanced melanomas, we have 
begun to make great improvements in treatment through the use of immunotherapies 
and targeted therapeutic approaches. The focus has shifted to anti-CTLA4 and anti-PD1 
antibodies which take advantage of immunogenic propensity of melanoma and 
inhibitors of BRAF and MEK which target a constitutively active signal transduction 
pathway present in approximately half of all melanoma patients. 
The first treatment to improve the survival of stage IV melanoma patients was 
Ipilimumab, which is an antibody-based therapy that modulates T-cell response 52. As a 
first-line therapy, ipilimumab plus dacarbazine resulted in a 2-month increase in median 
survival compared to dacarbazine alone, 11.2 months for the combination compared to 
9.1 for dacarbazine alone 52,54. With a 1-year survival of 47.3% compared to 36.3% for 
dacarbazine alone, ipilimumab led to durable responses with some patients continuing 
to show a complete response after 108 weeks 52,54. Another antibody-based 
immunotherapy, nivolumab, has also proven to have significant activity against 
metastatic melanoma. This immunoglobulin G4-blocking antibody against the T-cell 
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programmed death-1 checkpoint protein (PD1) was well tolerated at all doses in a 
phase I study involving 90 patients 55.  In patients who were both ipilimumab-refractory 
and –naïve, the vaccine produced a 25% RECIST response rate and a disease control 
rate of 46% with responses lasting up to 140 weeks 55. 
 
In vitro targeting of BRAF 
The identification of BRAF mutations in melanoma led to the development of a number 
of small molecule BRAF kinase inhibitors that are now undergoing intensive preclinical 
and clinical investigation. The first putative BRAF inhibitor to be thoroughly investigated 
in melanoma was the multi-kinase inhibitor sorafenib (BAY43-9006, Nexxavar) 56. 
Although sorafenib was originally developed as a CRAF inhibitor, it also had some 
activity against BRAF and was the first kinase inhibitor available for evaluation in BRAF 
mutant melanoma 57. In animal xenograft studies, sorafenib treatment led to minor 
levels of regression in BRAF V600E mutated melanoma and induced limited levels of 
apoptosis 25,57. Subsequent pre-clinical investigations showed sorafenib to be a 
relatively weak inhibitor of BRAF, with many off-target effects (including inhibition of 
VEGFR, PDGFR, FLT-3 and p38 MAP kinase 56,58), it was therefore concluded that any 
anti-melanoma activity seen to sorafenib was independent of its effects upon BRAF 
inhibition 59.  Following the evaluation of sorafenib, a new generation of highly specific 
and potent BRAF inhibitors has been developed. These drugs show a greater selectivity 
for mutant BRAF and have fewer off-target effects; the list of those currently under 
investigation includes: SB590885, dabrafenib (GSK2118436), PLX4032 (RG704, 
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vemurafenib), AZ628, XL281 and GDC-0879. Of these, the two that have been most 
comprehensively investigated are vemurafenib and its analogue PLX4720 60-62.  
Consistent with the role of BRAF/MAPK signaling in the regulation of cell growth, 
treatment of BRAF V600E mutated melanoma cell lines with pharmacological inhibitors 
of BRAF leads to a profound G1 phase cell cycle arrest. Indeed, the BRAF inhibitors 
SB590885 63, AZ628 64 and PLX4720 60 all have cytostatic effects upon melanoma cell 
lines harboring the BRAF V600E mutation. Significantly, the more potent BRAF 
inhibitors, such as vemurafenib /PLX4720, are also pro-apoptotic in a large proportion of 
BRAF mutant melanoma cell lines – an effect that was well correlated with the ability of 
the drug to induce BIM expression 30,40.   The effects of vemurafenib were noted to be 
BRAF mutation specific, and equivalent responses were seen in melanoma models with 
both heterozygous and homozygous BRAF mutations 61. Little effect was observed in 
cell lines and xenografts if both BRAF alleles were wild-type 61. Not all BRAF mutated 
melanoma cell lines were similarly sensitive to vemurafenib and PLX4720, with some 
cell lines exhibiting intrinsic resistance 65-67. Responses to vemurafenib and PLX4720 in 
human melanoma xenograft models were impressive; with either partial or complete 
responses observed in all cases, with a close relationship observed between drug 
exposure and response within individual xenograft models 61,68. The structure and 
kinase selectivity of vemurafenib was recently published, and showed the drug to be a 
pan-Raf inhibitor (IC50: BRAF V600E: 31 nM, wild-type BRAF: 100nM, CRAF 48: nM) 
with significant inhibitory activity (<100nM) against a number of other kinases (ACK1, 
MAP4K5 and SRMS) 61. The importance of these other kinases for the melanoma 
specific effects of vemurafenib remains to be determined 61. Another BRAF inhibitor 
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currently exciting much interest in both the pre-clinical and clinical arenas is dabrafenib, 
an ATP-competitive inhibitor of BRAF V600E/D/K, wild-type BRAF and CRAF 62. 
 
Clinical targeting of BRAF 
Sorafenib was the first RAF inhibitor to enter clinical development in patients with 
melanoma 69. In the initial series of studies patients were not selected on the basis of 
genotype and although some responses were seen, these were not correlated with 
BRAF mutational status 69. Large phase III randomized studies of sorafenib in 
combination with chemotherapy were associated with low response rates and there was 
little evidence that the effects of sorafenib observed were mediated through BRAF 
inhibition 58,70. 
Clinically, the most highly studied of the new class of BRAF specific inhibitors is 
vemurafenib. In the phase I clinical trial, 80% of melanoma patients (n=32) selected for 
the presence of the BRAF V600E mutation responded to PLX4032 (dosed at 240mg/kg 
- 960 mg/kg BID) and showed significant levels of tumor regression 71. 
Pharmacodynamic studies (inhibition of Ki67 and pERK staining in pre- and post-
treatment paired biopsies) suggested that >80% BRAF inhibition was required for 
clinical activity to be observed. It was further noted that inhibition of cytoplasmic pERK 
levels, but not inhibition of nuclear pERK levels, correlated well with tumor response 61. 
In line with preclinical studies showing the importance of mutated BRAF for the 
metabolic activity of melanoma cells, vemurafenib treatment was also observed to 
significantly diminish tumor 18F-fluoro-deoxyglucose (18F-FDG) uptake as measured by 
positron emission tomography (PET) imaging 61,71,72. Vemurafenib was generally well 
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tolerated with the most common side effects being rash, arthralgia, photosensitivity and 
fatigue. Intriguingly, >23% of patients rapidly (mostly <12 weeks of treatment) 
developed squamous cell carcinomas (SCC) of the keratoacanthoma (KA) type on 
areas of sun exposed skin 71. These tumors were removed surgically and did not recur. 
In the phase II BRAF In Melanoma (BRIM)-2 trial, 132 patients received 960mg of 
vemurafenib BID. The primary endpoint was best overall response, with duration of 
response, progression free survival, overall response and safety as the secondary 
endpoints. In this trial, 52.3% (n=69) of patients had a complete (2.3%) or partial 
response (50%), 29.5% (n=39) had stable disease and 13.6% (n=18) had progressive 
disease. Average duration of response was 6.8 months and median progression free 
survival was 6.2 months 73. Reported side effects were similar to those from the phase I 
trial, with 24% of patients developing KA. In phase III trial of vemurafenib (BRIM-3) in 
which 675 patients were randomized 1:1 against dacarbazine, the median overall 
survival for the vemurafenib-treated group was 13.6 months versus 9.7 months for 
dacarbazine74. With such a significant advantage for patients treated with vemurafenib, 
25% of the patients who were initially on the dacarbazine treatment arm crossed over to 
the vemurafenib arm74. Data from this trial led to FDA approval of vemurafenib for the 
treatment of disseminated melanoma in August of 2011. 
Dabrafenib is a highly potent small molecule BRAF inhibitor (In vitro kinase selectivity: 
BRAF; V600E – 0.6 nM, V600K – 0.5 nM, V600D – 1.9 nM, wild-type BRAF – 12 nM, 
CRAF – 5nM) that was evaluated clinically in BRAF mutant melanoma. The phase I/II 
clinical trial of dabrafenib differed from that of the vemurafenib study by including 
melanoma patients with non-V600E BRAF mutations (V600K and V600D) and 
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individuals with brain metastases 73. In the study population 77% harbored V600E 
BRAF mutations and 19% harbored V600K BRAF mutations. Like vemurafenib, 
response rates to dabrafenib were very impressive. In the BRAF V600E mutated 
melanoma cohort, the overall response rate was 77%, and 44% of BRAF V600K 
mutated melanoma patients (4/9) also showed a response 73. Progression free survival 
was 8.3 months. Significantly, dabrafenib was found to be active in melanoma patients 
with untreated brain metastases (n=10), with magnetic resonance imaging (MRI) studies 
confirming partial responses in 3 out of 10 patients. Overall, 9 out of 10 of the patients 
with brain metastases showed some level of response, with the responses in the brain 
matching those achieved at other organ sites 73. The drug was generally well-tolerated 
and side-effects were mild. Like vemurafenib, the development of SCC of the KA type 
was noted in patients treated with dabrafenib (>70 mg BID). Pharmacodynamic analysis 
showed 150mg of dabrafenib BID twice daily to inhibit intratumoral phospho-ERK by 
>90%, reduce expression of Ki67, induce expression of the cell cycle inhibitor p27 and 
decrease 18F-FDG-PET uptake. Interestingly, it was noted that increased dosing of 
dabrafenib up to 300-600mg did not result in proportional increases in plasma drug 
levels suggesting that hepatic metabolism was being induced. The drug is known to 
have a number of metabolites, at least three of which are highly active.  
All of the BRAF inhibitors evaluated so far, including sorafenib, vemurafenib, dabrafenib 
and XL281 have induced proliferative squamous lesions in the skin 61,71.  These lesions 
occur at sun-exposed skin sites, are frequently rapidly growing and can be managed 
with surgery or other local control measures. There is now strong preclinical evidence 
that BRAF targeted agents may have direct growth promoting effects upon initiated, but 
 16 
not fully transformed cells. Whereas BRAF inhibitors such as PLX4720 and GDC-0879 
inhibit the activation of BRAF/MEK/ERK in BRAF mutant cell lines, they are known to 
increase MEK/ERK signaling in cell lines with RAS mutations and constitutive activity in 
receptor tyrosine kinases such as HER2 75-77. From a mechanistic standpoint it has 
been shown that wild-type Raf kinase activation induces Raf dimerization. The 
paradoxical increase in MAPK signaling that occurs when BRAF is inhibited in tumor 
cells that are BRAF wild-type arises as a result of increased CRAF-CRAF dimer 
formation that in turn activates MEK 78,79. In addition to this, preclinical studies have also 
shown vemurafenib to enhance FAK signaling in NRAS mutant melanoma cells, which 
together with increased MAPK activity, increases invasive potential 75. There is also 
evidence that BRAF inhibition increases the survival of NRAS mutant tumor cells, in part 
by modulating Mcl-1 expression 77. A recent study examined a cohort of 35 squamous-
cell carcinomas and keratoacanthomas taken from patients undergoing BRAF inhibitor 
treatment and found that 60% of the specimens harbored Ras mutations, with HRAS 
Q61L being the most common 80,81. It was noted that BRAF inhibition did not initiate 
carcinogenesis in a HRAS Q61L mouse model, but instead stimulated the growth of 
cells harboring the HRAS mutation 80. This growth-stimulatory effect was blocked by 
concurrent MEK inhibitor treatment 80. Taken together, these results all suggest a need 
for the careful screening of melanoma patients for the BRAF mutation prior to the 
initiation of BRAF inhibitor therapy, with additional consideration for intra-tumoral 
genetic heterogeneity. 
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Mechanisms of intrinsic BRAF inhibitor resistance 
Although the presence of an activating BRAF mutation generally predicts for a response 
to BRAF inhibitors, a significant proportion of BRAF V600E mutated melanoma cell lines 
show signs of intrinsic drug resistance 30,66,67. Similar findings were observed in the 
phase I clinical trial of vemurafenib, where ~20% of the patients whose melanomas 
harbored the BRAF V600E mutation did not meet the RECIST criteria threshold for a 
response 71. Melanomas are known to have complex mutational profiles and harbor 
concurrent alterations in many genes including CDK2, CDK4, MITF and AKT3. How 
these genes and possibly others impact upon the biological behavior of melanoma cells 
and modulate the response to BRAF inhibitors is not yet understood.  
In melanoma cells, constitutive BRAF/MEK/ERK signaling drives cell cycle entry and 
uncontrolled growth by increasing cyclin D1 expression. It is now well established that 
inhibition of BRAF in BRAF V600E mutant melanoma cell lines leads to both inhibition 
of cyclin D1 expression and cell cycle arrest. A recent array comparative genomic 
hybridization (aCGH) analysis of a large panel of melanoma cell lines and tumor 
specimens showed 17% to harbor a BRAF V600E mutation in conjunction with 
amplification of cyclin D1 82. In Western Blot experiments, the amplified cell lines had 
increased cyclin D1 protein expression and showed intrinsic resistance to SB590885 82. 
Overexpression experiments showed the introduction of cyclin D1 into previously drug 
sensitive cell lines to facilitate cell cycle entry even when BRAF was inhibited 82. 
There is already good evidence from the breast cancer field that the expression and 
mutational status of the tumor suppressor PTEN is an important predictor of intrinsic 
resistance to targeted therapy agents such as trastuzamab and gefitinib 83. In these 
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instances, tumors that are PTEN negative, or those with high basal PI3K/AKT signaling 
showed a marked impairment of therapy-induced apoptosis and were associated with 
significantly worse therapeutic responses 83. Likewise, Nathanson et al. were able to 
demonstrate a trend for shorter progression-free survival on dabrafenib therapy in 
BRAF V600E/K melanoma patients with concurrent loss or mutation of PTEN84. Our 
studies support these ideas and identified loss of PTEN, observed in >10% of 
melanoma specimens, as being predictive for an attenuated apoptotic response 
following treatment with PLX4720 30. In the context of PTEN loss, BRAF inhibition led to 
an increase in AKT signaling that suppressed the pro-apoptotic protein BAD. The 
phosphorylation of BAD by AKT at Ser99 prevents the binding of BAD to Bax and 
relieves the antagonism of Bax on Bcl-2 and Bcl-XL 34. In addition, the increase in AKT 
signaling observed following BRAF inhibition was also noted to suppress the expression 
of BIM through the phosphorylation and subsequent nuclear export of the transcription 
factor FOXO3a 30. It was shown that intrinsic BRAF inhibitor resistance could be 
overcome by treating the BRAF V600E/PTEN null melanoma cell lines with the 
combination of a BRAF inhibitor and a PI3K inhibitor. This dual BRAF/PI3K inhibition 
restored the nuclear accumulation of FOXO3a, upregulated BIM expression and 
significantly enhanced the level of apoptosis 30. In further support of a role for AKT 
activation in intrinsic BRAF inhibitor resistance, others have shown that the 
overexpression of myristolated (constitutively active) AKT3 prevents PLX4720-induced 
apoptosis through the downregulation of both BIM and BMF 35. 
FOXO3a is a member of the Forkhead family of transcription factors that regulates cell 
survival and growth through the activation or suppression of a diverse array of 
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oncogenesis-related genes such as BIM, Fas-Ligand, cyclin D1 and GADD45 85. 
Inactivation of FOXO3a occurs as a result of its phosphorylation by AKT/SGK (at 
Threonine-32, Serine-253 and Serine-315), ERK1/2 (at Serine-294, Serine-344 and 
Serine-425), CK1, IKKB, CDK2 and AMPK; which leads in turn to its nuclear exclusion 
and subsequent proteasomal degradation 85. There is good evidence that inactivation of 
FOXO3a is a pre-requisite for the transformation of many cell types, and cytoplasmic 
FOXO3a accumulation is known to be a negative prognostic factor for breast cancer 85. 
Studies in other tumor systems, including a limited number of melanoma cell lines, have 
also linked intrinsic MEK inhibitor resistance to the impaired activation of FOXO3a and a 
subsequent reduction in BIM promoter activity 86. In this instance the combination of the 
MEK inhibitor AZD6244 with an inhibitor of AKT (API-2) was found to restore the 
nuclear localization of FOXO3a, upregulate BIM expression and enhance the levels of 
apoptosis 86.  
Although the mechanisms underlying the BRAF inhibitor-induced increase in AKT 
signaling have not been fully elucidated, there is some suggestion that increased insulin 
like growth factor (IGF)-I signaling may be involved 30. Similar findings implicating IGF-I 
signaling were also reported for melanoma cell lines showing intrinsic resistance to 
AZD6244 87. In this instance, intrinsic resistance could be overcome by treating the cells 
with AZD6244 in combination with an IGFR1, AKT or an mTORC1/2 inhibitor 87. Other 
studies, performed in multiple myeloma, have also shown that increased IGF-I signaling 
suppressed BIM expression through post-translational mechanisms and the 
deregulation of FOXO3a 88.  
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O’Connell and colleagues have demonstrated that signaling mediators of metastasis 
may also play a role in melanoma therapy resistance. Previously, Wnt5a-mediated 
metastasis was shown to be dependent on the receptor tyrosine kinase-like orphan 
receptor 2 (ROR2), with ROR2 expression occurring primarily in metastatic melanoma 
lesions 89. In their recent study, increased Wnt5A signaling through ROR2 was shown to 
promote a highly invasive and drug resistant phenotype in melanoma cells 90. A 
hypoxia-induced switch from ROR1-expressing cells to ROR2-positive melanoma cells 
conferred a 10-fold decrease in BRAF inhibitor sensitivity. Moreover, Wnt5a was also 
shown to be predictive of clinical response to BRAF inhibition 90. 
 
Mechanisms of acquired BRAF inhibitor resistance 
Although very encouraging, the clinical responses seen so far to vemurafenib and 
dabrafenib are relatively short-lived, with treatment failure and tumor progression 
occurring in the majority of cases. These observations, where an initial period of 
response is followed by relapse and resistance has been seen for every targeted 
therapy evaluated so far, including imatinib in CML and GIST 91,92, EGFR inhibitors in 
lung cancer and most recently hedgehog inhibitors in medulloblastoma 93,94. In nearly all 
of these examples, acquired drug resistance was associated with the acquisition of 
secondary mutations in the kinase being targeted. These mutations typically occurred at 
sites within the kinase ATP binding site that prevented the binding of drug to the 
hydrophobic pocket at so-called “gatekeeper” residues. Examples of clinically relevant 
gatekeeper mutations include T790M in the EGFR receptor and T315I in Bcr-ABL. A 
recent preclinical study identified the gatekeeper site in BRAF to be Threonine-259 
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(T259) 59. Studies on COS7 cells showed that mutation of BRAF at T259 conferred 
resistance to SB590885 and PLX4720 whilst allowing oncogenic BRAF kinase activity 
to be maintained 59.  Intriguingly, similar BRAF gatekeeper mutations have not been 
observed in either BRAF inhibitor resistant melanoma cell lines or biopsies taken from 
melanoma patients failing vemurafenib therapy 59. In the most detailed analysis 
performed so far, deep sequencing and ultra-deep sequencing of 14 biopsies from 
melanoma specimens from patients progressing on vemurafenib therapy showed no 
evidence of secondary BRAF mutations 95. Further in depth sequencing of exon 13 of 
BRAF (where the T259 residue lies) also failed to show the presence of additional drug-
induced BRAF mutations 95.  As a final confirmation that secondary BRAF mutations 
were not the mechanism of resistance in this patient cohort, the BRAF kinase was 
immunoprecipitated from vemurafenib resistant biopsy samples and found to retain drug 
sensitivity in an in vitro kinase assay 95.  
The emerging data instead suggest that a diverse array of BRAF inhibitor resistance 
mechanisms exist (Figure 3) 95-100. In a report by Villanueva and colleagues, the 
acquisition of BRAF inhibitor resistance led to a recovery of MAPK signaling and was 
associated with an increase in CRAF protein expression 64,97. Intriguingly, shRNA 
knockdown of CRAF alone did not restore drug sensitivity and it was instead found that 
shRNA knockdown of both ARAF and CRAF was required to overcome resistance 97. 
This flexible switching between RAF isoforms led to cross-resistance with other BRAF 
inhibitors but not MEK inhibitors and was not associated with acquired secondary 
mutations in BRAF, NRAS or PTEN. The nature of the upstream signal required for the 
ARAF/CRAF activation was not determined. Although inhibition of MEK was found to 
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decrease the proliferation of the resistant cells and led to a G1 phase cell cycle arrest it 
did not induce apoptosis. As this suggested that other compensatory pathways could be 
involved, the authors performed phospho-receptor tyrosine kinase (RTK) arrays and 
identified the insulin like growth factor receptor (IGFR)-1 as being constitutively 
activated in the resistant cells 97. Mechanistic studies showed IGFR1 signaling to 
mediate increased PI3K/AKT signaling in the resistant cells and that the resistance 
could be reversed by treating the cells with the combination of a PI3K and a MEK 
inhibitor or an IGF1R and a MEK inhibitor 97. The translational relevance of this finding 
was confirmed by the observation that 1 out of 5 melanoma specimens from patients 
failing vemurafenib expressed increased levels of IGFR1, and that one other specimen 
expressed increased levels of IGFR1 in conjunction with PTEN loss 97.  
A second recent paper showed acquired vemurafenib resistance to be associated with 
the upregulated expression of a number of RTKs 95. Of the RTKs identified, increased 
expression and tyrosine phosphorylation of the platelet derived growth factor receptor 
(PDGFR)-β was demonstrated to be responsible for conferring BRAF inhibitor 
resistance 95. The mechanism underlying the constitutive PDGFRβ signaling observed 
was not determined, but was not noted to be the result of an activating mutation or 
genomic amplification. The clinical relevance of this finding was demonstrated by 
increased level of PDGFRβ signaling in biopsies taken from 4 out of 12 patients failing 
vemurafenib therapy that was not observed in the pre-treatment biopsy samples 95. The 
potential role of PDGFRβ signaling in resistance was further confirmed by 
overexpression studies, where introduction of PDGFRβ into treatment naïve cells 
decreased sensitivity to vemurafenib. Somewhat surprisingly it was also found that 
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although siRNA knockdown of PDGFRβ reduced the growth and survival of the 
vemurafenib resistant cell lines, the resistant cell lines were not sensitive to the 
PDGFRβ inhibitor imatinib 95.  
A recent unbiased approach, in which 600 kinases and kinase-related open reading 
frames (ORFs) were expressed in melanoma cells identified nine candidate ORFs 
(including Axl, CRKL, ERBB2, FGR, MAP3K8, PAK3, CRAF, PKC-epsilon and PKC-
eta) capable of mediating resistance to the BRAF inhibitor PLX4720 99. This study 
confirmed earlier work demonstrating a role for increased CRAF expression in 
mediating resistance to AZ628 and further identified MAP3K8 (COT) as a new 
candidate for the RAF-independent activation of ERK 99. A number of cell lines were 
identified with genomic amplification of COT, all of which showed intrinsic BRAF and 
MEK inhibitor resistance. Further studies demonstrated that both COT shRNA 
knockdown and small molecule COT inhibitors reduced the MAPK signaling and 
survival of COT amplified cell lines. It was also shown that COT activated ERK through 
both MEK-dependent and independent mechanisms 99. In melanoma cell lines where 
COT was overexpressed by lentiviral vector, drug resistance was overcome by treating 
the cells with a combination of a BRAF and MEK inhibitor. The clinical relevance of 
increased COT expression in the resistant phenotype was confirmed in a limited 
number of melanoma samples from patients failing BRAF and MEK inhibitor treatment.   
As well as increased RTK activity, there is evidence that genetic alterations in the 
Ras/Raf/MEK/ERK pathway also mediate acquired BRAF inhibitor resistance. A genetic 
analysis of biopsies from a patient failing vemurafenib therapy revealed the presence of 
an activating NRAS (Q61K) mutation that was lacking in the original tumor 95. This 
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apparent switch in mutational status was accompanied by the reactivation of the MAPK 
pathway upon vemurafenib treatment and appeared to be a relatively rare occurrence 
(only 1 patient identified so far).  Of interest, it was noted that activating NRAS 
mutations were found in only 3 out of 6 sections from the same tumor specimen, 
suggesting the presence of different clonal populations. There is some evidence that 
melanomas consist of co-existent clones with different (e.g. both BRAF and non-BRAF) 
oncogenic mutations and at least two studies have now reported the existence of 
distinct BRAF mutant and NRAS mutant cells within the same melanoma specimen 
101,102. The possible polyclonal nature of melanoma was further suggested by a single 
cell BRAF sequencing study, where both BRAF mutant and wild-type cells were derived 
from the same tumor 103. If confirmed in a larger patient cohort, the issue of mutational 
polyclonality could have important clinical implications, particularly in light of the 
overwhelming pre-clinical evidence that BRAF inhibitors confer a growth advantage to 
NRAS-mutant melanoma cells 75,77.  
In addition to secondary Ras mutations, there is evidence from colon cancer that the 
genomic amplification of BRAF also mediates resistance to MAPK inhibition 104. 
Analysis of drug naïve cell cultures using fluorescence in situ hybridization (FISH) 
identified limited numbers of cells with high BRAF copy number 104. Treatment of these 
cultures with the MEK inhibitor AZD6244 led to an expansion of the BRAF amplified 
population, with resistance being reversed by the shRNA knockdown of BRAF 104. While 
the relevance of BRAF amplification to BRAF inhibitor resistance in melanoma is still 
under investigation, emergent evidence has implicated alternative splicing of the BRAF 
gene in BRAF inhibitor resistance. Poulikakos and colleagues identified abhorrently 
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spliced BRAF, including exons 4-8 which harbor the Ras binding domain, in a subset of 
cells resistant to vemurafenib 105. This study demonstrated that the p61BRAF(V600E) 
splice variant can dimerize in a Ras-independent manner, and that introducing a 
mutations which prevent  p61BRAF(V600E) dimerization were able to re-sensitize 
melanoma cells to BRAF inhibition 105. 
 
Other studies have shown that mutations in MEK can also mediate BRAF inhibitor 
resistance. A massively parallel sequencing study of one biopsy sample from a 
melanoma patient failing vemurafenib therapy identified a novel codon 121 mutation in 
MEK1 (C121S) that conferred increased kinase activity in in vitro studies 96. 
Overexpression of this novel MEK1 mutation in A375 melanoma cells was found to 
induce cross resistance to both MEK (AZD6244) and BRAF (PLX4720) inhibitors in vitro 
96.  
We still do not know whether therapeutic escape arises as the result of an evolutionary 
process within the melanoma or from the selection of pre-existing “resistant” clones that 
are already present prior to the initiation of therapy. Based upon the current data, both 
of these situations are likely to be true. A growing number of studies are now suggesting 
that the inherent phenotypic and genetic heterogeneity of cancer cell populations is a 
critical determinant of drug resistance. There is evidence that a transient drug-tolerant 
state can emerge through epigenetic means in individual cells, through activation of 
IGFR1 signaling and an altered chromatin state mediated through the histone 
demethylase RBP2/KDM5A/Jarid1A 106. The drug tolerant cells were identified in 
cultures derived from a number of tumor types and seemed to be important in the 
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escape response to both inhibitors of RTK signaling and cytotoxic chemotherapy drugs 
106. Interestingly, the drug tolerant population also emerged in cultures established from 
single cells, demonstrating the reversible, switchable nature of this phenotype. From a 
therapeutic standpoint, tolerance could be abrogated by the inhibition of IGFR1 
signaling or through use of histone deacetylase (HDAC) inhibitors 106. Of relevance to 
melanoma and BRAF inhibitor resistance, HDAC inhibition was found to induce at least 
some apoptosis in melanoma cells that were resistant to the BRAF inhibitor AZ628 106.  
The characterization of the pre-existing sub-population of cells that escape BRAF 
inhibitor therapy is key to managing resistance. New insights into the nature of drug 
tolerant cells have come from a recent study identifying a minor subset of melanoma 
cells that were required for tumor maintenance and expressed high levels of the H3K4 
histone demethylase Jarid1B 107. These cells tended to be present at low levels within 
the melanoma population, proliferated very slowly and underwent a marked expansion 
when treated with either BRAF inhibitors or cytotoxic chemotherapeutic drugs 107. 
Further study will be required to determine whether simultaneous treatment with 
inhibitors of BRAF and HDAC is sufficient to prevent the onset of resistance, and 
whether the expansion of Jarid1B expressing melanoma cells is a critical step in the 
emergence of drug resistance. 
 
Combination therapies 
Virtually every small molecule kinase inhibitor evaluated in cancer so far has shown a 
similar pattern of response, relapse and resistance. Melanoma seems to be unique in 
terms of the sheer diversity of resistance mechanisms identified. Every report to date 
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has identified a different resistance mechanism with further modes of therapeutic 
escape likely to be reported in the near future.  Why this should be so is open to 
speculation, but may be linked to the vast number of genetic mutations found in a 
typical melanoma (up to 30,000 mutations reported in one melanoma cell line 10).  It is 
possible that this high degree of mutational diversity accounts for the heterogeneity of 
resistance mechanisms observed. Therefore, the management of BRAF inhibitor 
resistance is likely to be achieved through combination therapy approaches 108. 
Although the resistance mechanisms identified so far are diverse, most seem to rely 
upon the reactivation of and dependence upon MEK/ERK signaling and increased 
signaling output through the PI3K/AKT/mTOR pathway. The finding that BRAF inhibitor 
resistance in melanoma is associated with re-activation of the MAPK pathway is not 
surprising. Melanomas harboring activating BRAF V600E mutations show a high degree 
of dependency upon MAPK and are exquisitely sensitive to pharmacological inhibitors 
of both BRAF and MEK. Indeed, a number of groups have shown pre-clinically that dual 
BRAF and MEK inhibition may prevent or delay the onset of resistance 98,99,104 and that 
dual BRAF/MEK and PI3K/AKT/mTOR inhibition has synergistically pro-apoptotic 
effects 109,110. Developing on the success of BRAF inhibition and in an effort to delay the 
onset of resistance mediated through reactivation of the MAPK pathway, the 
combination of BRAF and MEK inhibition has become the new standard of care for 
advanced melanomas today 98,111,112. The recent open-label study involving 247 patients 
with metastatic melanoma demonstrated a safe and efficacious combination of the 
BRAF inhibitor dabrafenib and MEK inhibitor trametinib, with a 9.4-month median 
progression-free survival in the combination group compared to 5.8 months in the 
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dabrafenib monotherapy group 112.  Interestingly, the combination has demonstrated 
fewer off-target toxicities such as pyrexia and cutaneous squamous-cell carcinoma than 
are associated with either monotherapy112. Clinical trials combining PI3K and BRAF 
inhibitors and BRAF and AKT inhibitors are ongoing. 
With the impressive individual successes of BRAF inhibitors and ipilimumab for 
treatment of disseminated melanoma, great interest has emerged to combining 
immunotherapy with targeted MAPK inhibition. Mechanistically, there is strong rationale 
for such combinations. Sumimoto et al. have reported that constitutively activated 
MAPK pathway, as observed with an oncogenic BRAF, is essential for immune evasion 
in melanoma cells through an increase in the production of a number of 
immunosuppressive cytokines, including IL-10, VEGF, and IL-6, from melanoma cells 
and the suppression of IL-12 production in dendritic cells 43. Recent evidence also 
suggests that treatment of melanomas with inhibitors of BRAF promote melanoma 
immunogenicity through enhanced antigen expression/recognition and infiltration of 
cytotoxic T lymphocytes 113-116. Despite the strong rationale for the combination of 
targeted MAPK inhibition with immunotherapy, early attempts at such combinations 
have been discouraging. The phase I clinical trial combining ipilimumab with 
vemurafenib was forced to close early due to severe hepatotoxicity of the combination 
117. One cohort of patients received vemurafenib and ipilimumab at full FDA-approved 
doses, starting with 1-month of vemurafenib (960mg BID) followed by simultaneous 
administration of vemurafenib and four infusions of ipilimumab, and a second cohort of 
patients received a similar regimen with a reduced dose of vemurafenib (720mg BID) 
117. The lack of initial success of combining immune-based therapies with targeted 
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therapies may not be indicative of the overall efficacy of such combinations, as their 
value may lie in careful planning of dose administration and therapy sequence. One 
promising case study reported an unusually long survival in a patient with melanoma 
brain metastasis. Balakan et al. reported inspiring effectiveness of palliative 
radiotherapy, chemotherapy, ipilimumab, stereotactic radiosurgery and vemurafenib, 
with the patient surviving for 40-months following melanoma metastasis to the brain 118. 
 
Microenvironment-mediated drug resistance 
Systemic drug therapies seldom lead to the cure of advanced malignancies, even in 
instances of extraordinary early responses. Even in cases of initial success of BRAF 
inhibition, responses were generally short-lived and relapse ensued in nearly every 
case. Treatment failure habitually occurred at the site of the original lesions, suggesting 
that resistance may result from incomplete tumor eradication and that the tumor 
microenvironment may have a crucial role in the development of resistance 119.  
The emergent evidence for therapeutic resistance implicates both tumor autonomous 
and microenvironment-mediated mechanisms of pro-survival adaptation 120-123. During 
melanoma progression, the cells lose contact with keratinocytes, their normal binding 
partners, and begin to interact with host endothelial cells and fibroblasts instead 124,125.  
The role for fibroblasts in mediating melanoma growth and resistance has been 
observed previously. Tumor-infiltrating fibroblasts have been identified in the stroma of 
metastatic melanomas and are phenotypically different from fibroblasts not associated 
with a tumor, showing a distinct pattern of activation and ECM/growth factor secretion 
126,127. One study has shown that conditioned media from melanoma cells is capable of 
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stimulating the secretion of the pro-invasive molecule glycosaminoglycan hyaluronan 
from human dermal fibroblasts128. Additionally, fibroblasts have been shown to promote 
blood vessel formation through recruitment of endothelial cell precursors as well as 
secretion of vascular endothelial growth factor (VEGF), suggesting that stromal 
fibroblasts may contribute to melanoma tumor angiogenesis 126,129,130. Recently, 
Straussman et al. have demonstrated that fibroblasts can promote melanoma cell 
survival during vemurafenib therapy via hepatocyte growth factor (HGF) secretion, 
reactivating downstream MAPK and PI3K signaling pathways 121. Other extra-cellular 
components have also been implicated in melanoma drug resistance. Recent evidence 
suggests that acquired BRAF inhibitor resistance may be driven through tumor-derived 
growth factors, such as epithelial growth factor (EGF), neuregulin (NRG) and insulin-like 
growth factor (IGF)-I 97,120,123. In multiple myeloma, adhesion of cancer cells to the 
extracellular matrix (ECM) has been shown to promote cell survival when the cells are 
treated with DNA-damaging chemotherapy drugs, with adhesion to fibronectin (FN) 
conferring a decrease in sensitivity to melphalan 131-133. Although emerging evidence 
has shed some light on microenvironment-mediated drug resistance, the “protective 
sanctuary” arising from the interaction between melanoma cells and their 
microenvironment is still not well understood, with the direct signaling between normal 
and tumor cells remaining largely uncharacterized.  
 
ECM/Integrin signaling 
At first, it was thought that the role of extracellular matrix (ECM) existed simply to 
provide physical support for the cells it surrounds, however it has become more 
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apparent recently that ECM mediates a complex crosstalk between the cells and their 
microenvironment, modulating the cell motility, proliferation, differentiation and survival 
134,135. There are four families of macromolecules that can make up the ECM: collagens, 
elastins, glycosaminoglycans and matrix glycoproteins 135. Among the matrix 
glycoproteins, fibronectin has been studied the most extensively, and has been shown 
to be crucial for cell adhesion, migration, oncogenic transformation, and most recently in 
drug resistance 131-133,135-137. Fibronectin has also previously been implicated in cancer 
cell metastasis. One group has shown that synthetic peptides that interfere with cell-
fibronectin binding have been able to block malignant cell metastasis in a B16-F10 
murine melanoma model 134. Integrin α5/β1 is the main fibronectin receptor and 
mediates the bidirectional signaling between the cell and the ECM/microenvironment 
through binding of the RGB domain on FN 135. Integrins are transmembrane adhesion 
receptors that function as alpha- and beta- heterodimers and do not have kinase activity 
of their own 135,138. The 18 alpha and 8 beta subunits can combine to form at least 25 
distinct receptors 138. Integrins control the bi-directional signaling by forming complexes 
with other signaling molecules, such as FAK, SHC, ILK and various receptor tyrosine 
kinases 138,139. The importance of integrin signaling in melanoma has been highlighted 
in a number of studies, largely focusing on their role in melanoma progression and 
metastasis. Many studies have indicated that the expression patterns of integrins often 
vary during malignant transformation. Albelda and colleagues showed the expression of 
the β3 subunit to be linked to cells in the vertical growth phase or metastatic melanomas 
140. Up-regulation of integrin α2/β1, α3/β1, α4/β1, α5/β1, α6/β1 and α7/β1 has been 
linked to an increase in metastatic potential 141. MAPK and the PI3K/AKT signaling 
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cascades, which are both vital in melanoma growth, survival and motility, are two 
pathways in which growth factor- and integrin-mediated signaling converge. FAK and 
SHC modulate integrin signaling by activating ERK downstream, and PTEN, which is a 
negative regulator of the PI3K signaling, has also been shown to dephosphorylate both 
FAK and SHC 138. Therefore, cells lacking a functional form of PTEN may be able to 
enhance signaling through integrins and the PI3K/AKT signaling cascade. 
With the recent work from our lab and others identifying BRAF-mutant PTEN- 
melanoma cells to be intrinsically less sensitive to the BRAF inhibitor vemurafenib 142-
144, the focus of this work was to elucidate the mechanism of drug resistance in this 
genetic subgroup of melanomas that allows them to escape BRAF inhibitor therapy. We 
hypothesize that this subset of melanomas are able to remodel their extracellular matrix 
and rely on complex, integrin-mediated bi-directional signaling with the 
microenvironment in order to overcome BRAF inhibitor-induced apoptosis. 
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Figure 1. Role of mutant BRAF in preventing apoptosis in melanoma cells. The 
inhibition of BRAF decreases the phosphorylation of BIM through the MEK/ERK 
pathway, preventing its proteasomal degradation. Once stabilized, BIM antagonizes the 
anti-apoptotic proteins Bcl-2 and Bcl-XL and leads to apoptosis induction. In PTEN-null 
melanoma cells, BRAF inhibition leads to the increased PI3K/AKT-mediated 
phosphorylation of FOXO3a resulting in reduced BIM transcription. Inhibition of BRAF in 
PTEN null melanoma cells also impairs apoptosis through the AKT-mediated 
phosphorylation and inactivation of BAD. The phosphorylation of BAD prevents its 
binding to Bax and relieves the antagonism of Bax on Bcl-2 and Bcl-XL. Intrinsic BRAF 
inhibitor resistance in the PTEN-null cells can be overcome through dual inhibition of 
BRAF and PI3K. 
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Figure 2. Mutated BRAF drives the invasion of melanoma cells. Mutant BRAF 
regulates melanoma cell invasion through MEK/ERK-mediated signaling to RND3 and 
Rho/ROCK/LIM-mediated Cofilin phosphorylation. It is also known that ERK can 
upregulate BRN2 expression leading to the downregulation of PDE5A and cytoplasmic 
accumulation of cGMP and Ca2+. Increased intracellular calcium in turn leads to 
increased MLC2 phosphorylation, contractility, and invasion. 
 
 
 
Figure 3. Mechanisms of acquired resistance to BRAF inhibitors. Multiple 
mechanisms of acquired BRAF inhibitor resistance have been identified. BRAF V600E 
melanoma cells chronically treated with BRAF inhibitors acquire drug resistance via 
switching between the three isoforms of RAF (ARAF, BRAF, CRAF) to activate the 
MAPK pathway. Increased IGFR1 and PDGFR signaling may also allow for resistance 
by activating PI3K/AKT signaling as well as other pathways. Resistance can also arise 
following the reactivation of the MAPK pathway, this can occur following the acquisition 
of activating mutations in NRAS (Q61K) and MEK (C121S) and the increased 
expression of the MAP3K8 (COT). 
 35 
 
 
 
 
 
CHAPTER II: 
MATERIALS AND METHODS 
 
Cell culture and reagents 
The 1205Lu, WM9, WM793, WM164, WM983A and 451Lu melanoma cells lines as well 
as the FF2504, FF2507 and FF2447 human primary skin fibroblasts were a generous 
gift from Dr. Meenhard Herlyn (The Wistar Institute, Philadelphia, PA) and were 
genotyped as being BRAF V600E mutant. WM793TR cell line was a generous gift from 
Dr. Andrew Aplin (Kimmel Cancer Center, Philadelphia, PA). Inducible expression of 
PTEN was achieved by treatment of cultures with 100 ng/mL doxycycline. WM9-GFP 
was a generous gift from Dr. Peter Forsyth (Moffitt Cancer Center, Tampa, FL). The 
identities of all cell lines were confirmed by Biosynthesis Inc (Lewisville, Tx) through 
STR validation analysis.  Cell lines were maintained in 5% FBS/RPMI-1640. Acidic 
media experiments were carried out using DMEM/F12 containing 25mM Pipes, 25mM 
HEPES, and 10% FBS, then pH was adjusted using NaOH.  Human Fibronectin and 
HGF were purchased from Invitrogen (Life Technologies, Carlsband, CA), and 
recombinant human TGF β1, EGF, and NRG-1 were from R&D Systems (Minneapolis, 
MN). 
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Phospho-proteomics sample preparation, LC-MS/MS and analysis 
Briefly, cells were lysed in denaturing buffer (100 mM ammonium bicarbonate with 8M 
urea) followed by protein reduction, alkylation and trypsin digestion. The tryptic peptides 
were then desalted. Following lyophilization, phosphotyrosine-containing peptides were 
enriched by immunoprecipitation with immobilized anti-phosphotyrosine antibody p-Tyr-
100 (Cell Signaling Technology). A nanoflow ultra high performance liquid 
chromatograph (RSLC, Dionex, Sunnyvale, CA) coupled to an electrospray ion trap 
mass spectrometer (LTQ-Orbitrap, Thermo, San Jose, CA) was used for tandem mass 
spectrometry peptide sequencing experiments.  Sequest and Mascot 145 searches were 
performed, allowing less than 2 missed tryptic cleavages and searching for STY 
phosphorylation, methionine oxidation, and carbamidomethylation of cysteine as 
variable modifications. The results were summarized in Scaffold 3.0. Label-Free 
quantification was performed using MaxQuant (ver 1.2.2.5) 146. Each treatment cohort 
was analyzed in duplicate and average intensities for each of the unique phospho-
peptides were calculated. Peptides with PEP score lower than 0.05 were used for 
subsequent analysis. Peptides matching reversed protein sequences were excluded 
from analysis as false positives. A heatmap of pY quantification was generated using 
MultiExperiment Viewer (version 4.8.1)147 based on averaged and log transformed pY 
intensity scores, excluding any peptides with pY intensity of 0 in either or both control or 
treatment cohorts following MaxQuant quantification. In cases when multiple quantified 
peptides mapped to a single protein, the same peptide was compared among control 
and treated sample quantifications. Pathway enrichment analysis was carried out using 
GeneGo Pathway Maps in Metacore (Thomson Reuters). Protein interaction analysis 
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was performed using Interactome Analysis Workflow tool in Metacore. Cytoscape (ver 
2.8.3) was utilized for analysis and visualization of interactions among differentially 
phosphorylated peptides, including their degree of connectivity. Additional pathway 
analysis was performed using Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway database 148, specifically focusing on a single pathway which mapped the 
greatest number of differentially phosphorylated proteins identified in the phospho-
proteomic analysis. Proteins from the pathway which matched proteins identified to be 
differentially phosphorylated in the phospho-proteomic analysis were visualized in pink. 
 
Western blotting  
Proteins were extracted using RIPA lysis buffer (0.5M Tris, Triton X-100, Na-
deoxycholate, 10% SDS, NaCl, 0.5M EDTA) containing Complete Mini protease 
inhibitor cocktail tablet (Roche, Indianapolis, IN). Total protein was quantified using 
Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL). Protein extracts were 
resolved on Novex 8-16% Tris-glycine gels (Life Technologies, Carlsband, CA). 
Proteins were electrophoretically transferred onto PVDF membranes (Millipore, Bedford, 
MA) for 1.5 hours and washed in Tris-buffered saline (TBS; 100 mmol/L Tris-HCl, pH 
7.5, and 150 mmol/L NaCl) containing 0.1% Tween-20. Membranes were blocked for 1 
hour in 5% non-fat dry milk/TBST. Primary antibody incubations were performed 
overnight at 4°C in 5% BSA/TBST followed by washing and then a 1-hour incubation 
with isotype-specific HRP-conjugated secondary antibody diluted in 5% milk/TBST 
(Amersham Pharmacia, Little Chalfont, UK). Immunocomplexes were visualized using 
the enhanced chemiluminescence substrate (PerkinElmer, Waltham, MA) and detected 
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on autoradiography film (Denville Scientific, Metuchen, NJ). Uniform protein loading was 
confirmed by blotting for GAPDH. The antibodies to PTEN, Integrin α5, Integrin β1, 
BRAF, phospho-AKT S473, total AKT, Caspase 7, phospho-ERK, total ERK, phospho-
Met (Tyr1234/1235), phospho-EGFR (Y1172), phosho-HER3 (Y1289), TGFβ and MCL-
1 were from Cell Signaling Technology (Beverly, MA). Laminin 5, α-SMA and SNAIL 
antibodies were purchased from Abcam (Cambridge, MA) while the antibodies against 
Vitronectin, and SLUG were from Santa Cruz Biotechnology (Santa Cruz, CA).  
Fibronectin antibody was purchased from BD (San Jose, CA), GAPDH was from Sigma 
(St. Luis, MO), and Phalloidin was from Invitrogen (Life Technologies, Carlsband, CA).  
 
Immunofluorescent staining  
Melanoma and primary skin fibroblast cells were plated on glass coverslips in six-well 
plates and incubated overnight prior to treatment. Cells were then fixed using 4% 
paraformaldehyde solution (Electron Microscopy Sciences, Hatfield, PA) and 
permeabilized with 0.2% Triton X-100 prior to being blocked in 1% BSA/PBS. 
Coverslips were incubated with primary antibodies overnight at 4°C. Coverslips were 
then washed in PBS, incubated with secondary antibodies for 1 hour at RT, and washed 
again in PBS and sterile water. Coverslips were mounted with ProLong Gold antifade 
reagent with DAPI (Life Technologies, Carlsband, CA) and imaged using confocal 
microscopy. Images were analyzed using Definiens® Developer v2.0 (Definiens AG, 
Munich, Germany) software suite. The total fluorescence intensity was normalized to 
the number of nuclei for monocultures or to the number of GFP-positive cells in co-
cultures.  
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RNA interference 
Cells were plated and left to grow overnight in 5% FBS/RPMI. 5%FBS/RPMI media was 
replaced with Opti-MEM (Invitrogen). Fibronecin pool, Fibronectin siRNA A 
GACUGGUGGUUACAUGUUAtt, Fibronectin siRNA B CGCAUCACUUGCACUUCUAtt, 
Fibronectin siRNA C GAUCCUGUCUACUUCACAAtt, Integrin α5 siRNA A 
GUCAGAAUUUCGAGACAAAtt, Integrin α5 siRNA B CCACUGACCAGAACUAGAAtt,  
Integrin β1 siRNA A GAGAUGAGGUUCAAUUUGAtt, Integrin β1 siRNA B 
GAUGAGGUUCAAUUUGAAAtt, (25nM, Santa Cruz), Integrin α5, Integrin β1 and PTEN 
(all 25nM, Cell Signaling Technologies), and BRAF (25nM, Thermo Scientific) siRNA’s 
in complex with Lipofectamine 2000 (Invitrogen) were added. Scrambled, non-targeting 
siRNA’s were used as controls. A final concentration of 5% FBS in RPMI was added the 
next day. For fibronectin knockdowns, final concentration 1% FBS in RPMI was added 
next day. Cells were transfected for 24-72 hours prior to treatment. 
 
RTK and kinase arrays 
Phosphorylation levels of forty-two human receptor tyrosine kinases were determined 
using the Proteome Profiler Human Phospho-RTK Array Kit (R&D Systems). 
Phosphorylation levels of forty-three phosphorylation sites on human kinases were 
determined using the Proteome Profiler Human Phospho-Kinase Array Kit (R&D 
Systems). 
 
 
 
 40 
Animal studies 
Female BALB SCID mice (The Jackson Laboratory, Bar Harbor, ME), and female SHO 
mice (Charles River) were subcutaneously injected with 2.5 x106 cells per mouse. 
Tumors were allowed to grow to approximately 150 mm3 prior to dosing. Mice were 
administered D10001 control chow, AIN-76A 417 mg/kg PLX4720-formulated chow 
(Research Diets, New Brunswick, NJ), vehicle (0.5% methylcellulose, 0.2% Tween-80) 
oral gavage, or GDC-0941 oral gavage (150mg/kg) daily for 21 days. Mouse weights 
and tumor volumes (½ x L x W2) were measured every 48 hours. 
 
ELISA assays 
Fibronectin ELISA Kit was obtained from Millipore (Billerica, MA). TGFβ1 and HGF 
ELISA kits were purchased from R&D Systems (Minneapolis, MN). Neuregulin ELISA 
Kit was from Abcam (Cambridge, MA).  
 
qRT PCR 
Cells were treated for 72 hours then total RNA was isolated using Qiagen’s RNeasy 
mini kit. The following TaqMan® Gene Expression Assays primer/probes were used: 
Hs00365052_m1 (Fibronectin), P/N 4319413E (18S) and Hs99999905_m1 (GAPDH). 
The 18S + GAPDH data were utilized to normalize Fibronectin. qRT-PCR reactions 
were performed as previously described 149.  
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Flow cytometry 
Cells were grown in 6 well tissue culture plates overnight, then treated with vehicle 
(DMSO) 3 µM vemurafenib, 3 µM GDC-0941, or the two drugs in combination for 72 
hours. In some studies, cells were transfected with non-targeting siRNA or siRNAs 
targeting fibronectin, integrin α5, or integrin β1 for 24 hours prior to treatment and 
harvested after 48 or 72 hours of treatment. Cells were then washed with 1x Annexin V 
Binding Buffer (BD, San Jose, CA), resuspended in 100 µL of binding buffer containing 
2 µL APC-conjugated Annexin V (R&D Systems, Minneapolis, MN) and 25 nmol/L 
tetramethylrhodamine, methyl ester, perchlorate (TMRM; Molecular Probes, Eugene, 
OR). Cells were incubated at 37°C for 15 min before being analyzed for Annexin V 
fluorescence and TMRM retention using flow cytometry. Gates were delineated based 
on regions of distinct populations. 
For analysis of phospho-AKT and cleaved PARP, FF2504 human primary skin 
fibroblasts (3.0 x 105 cells) were plated in 6-well plates and allowed to attach overnight. 
GFP-tagged WM9 melanoma cells (3.0 x 105 cells) were then plated either on plastic or 
on FF2504 fibroblasts and incubated overnight. Cells were then treated with single 
agent or different combinations of 3µM vemurafenib (BRAFi), 3µM GDC-0941 (PI3Ki), 
200nM crizotinib (METi), and 1µM lapatinib (HER2i) for 24 hours prior to being collected 
by scraping, fixed with 4% paraformaldehyde for 10 minutes at RT and permeabilized 
with 100% cold methanol for 1 hour at RT. Cells were then washed with incubation 
buffer (0.5% bovine serum albumin in PBS) and stained with phospho-AKT conjugated 
to AlexaFluor 647 (Ser473, Cell Signaling Technology, Beverly, MA) and cleaved PARP 
conjugated to PE (BD, San Jose, CA) in incubation buffer for 1 hour at RT. Cells were 
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then washed again and analyzed by flow cytometry. Phospho-AKT gates were 
delineated based on a shift between control and GDC-0941-treated group on plastic. 
Cleaved-PARP gates were delineated based on regions of distinct populations.  
 
LC-MRM 
LC-MRM was performed as described in 150. Protein expression was determined using 
the ratio of peak area of the native peptide to corresponding internal standard; 
normalization of results was performed using GAPDH. Data were then normalized to the 
non-targeting siRNA controls and graphed to show the changes in expression after 
transfection and drug treatment. 
 
Colony formation 
Cells were seeded out into six-well plates at 1 × 104 per well and grown overnight 
before being treated with vehicle, 3   µM vemurafenib, 3 µM GDC-0941, or the two drugs 
in combination. Cells were left to grow for 2 weeks with new drug added twice per week. 
Wells were washed with PBS and stained with crystal violet solution (50% methanol + 
50% H2O + 0.5% crystal violet).  
 
Growth inhibition assay 
Primary human skin fibroblast cells were plated at a density of 10 x104 cells per ml and 
left to grow overnight before being transfected with non-targeting siRNA or siRNA 
targeting fibronectin for 96 hours in serum-free conditions. Cells were then incubated 
with Alamar Blue reagent followed by a measurement of absorbance at 570 nm. 
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TMA and patient specimens 
A tissue microarray (TMA) containing a spectrum of melanoma specimens was 
constructed and analyzed under approved protocols by the Institutional Review Board at 
the University of South Florida. It contained samples from four groups: primary 
cutaneous melanoma, lymph node metastases, dermal/subcutaneous metastases, and 
visceral metastases. After identification of tumor tissue, two 1.5 mm cores were 
obtained from each donor block. For the TMA, a single core from each block was 
positioned on a grid of 100 samples processed with the Beecher Microarray System. 
Targeted gene sequencing was performed on extracted DNA from the second core, and 
analyzed via the Sequenom platform (MassARRAY Analyzer 4 and Melacarta™ Panel). 
Clinical data was collected on the patients. Medical records and the social security 
death index were searched for demographic, pathology, staging and recurrence/survival 
data. Analyses were performed using SPSS and SAS software.  TMA sections were 
evaluated for total FN and PTEN expression via IHC with optimized anti-FN (Abcam, 
Cambridge, MA) and anti-PTEN (Spring Bioscience, Pleasanton, CA) antibodies in the 
Tissue Core at Moffitt Cancer Center. TMA was stained using a Ventana Discovery XT 
automated system (Ventana Medical Systems, Tucson, AZ) following manufacturer's 
protocol with proprietary reagents. Detection was carried out using the Ventana 
ChromoMap Red kit with Hematoxylin counterstain. Staining intensity was scored by the 
dermatopathologist as follows: absent staining=0, weak staining=1, moderate 
staining=2, strong staining =3. For both markers, all tumor cells in the infiltrate showed 
diffuse, uniform staining. Dichotomous high and low FN levels were assigned based on 
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IHC scores of 0-1 and 2-3, respectively. PTEN dichotomous scoring was assigned as 
absent (IHC=0) versus present (IHC=1-3).  
 
Statistical analysis 
Results are reported as mean values, error bars indicating ± SEM. GraphPad Prism 6 
software was used to calculate statistical significance of magnitude of changes between 
different conditions was calculated using the parametric paired t-test with p-values 
depicted as follows: *p≤0.05, ** p≤0.01, *** p≤0.001, **** p≤0.0001. 
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CHAPTER III: 
RESULTS 
 
Phosphoproteomic screen identified adaptive changes in the signaling networks 
of PTEN- melanoma cell lines in response to BRAF inhibition. 
In order to characterize the vemurafenib-mediated adaptive changes in signaling, three 
BRAFV600E/PTEN- mutant melanoma cell lines were treated with either DMSO vehicle or 
vemurafenib (3 µM) for 24 hours. Then the tyrosine phosphorylated (pTyr) peptides 
were captured by immunoprecipitation and changes in the level of phosphorylation 
analyzed by mass spectrometry (Figure 4). Quantification of the tyrosine-
phosphorylated peptide intensities following BRAF inhibition using label-free MAXQuant 
revealed changes in 73-83 individual peptides, depending upon the cell line (Figures 5-
6)146. Heatmap visualization of the global changes in tyrosine phosphorylation 
highlighted pronounced changes in some peptide phosphorylation levels and subtle 
changes in others (Figure 5). Changes to 57 pTyr peptides were mutual to all three cell 
lines (Figure 6). GeneGO pathway analysis revealed enrichment of pathways 
associated with cytoskeletal remodeling, RTK signaling, integrin-mediated adhesion, 
FAK signaling and epithelial-to-mesenchymal transition (EMT) (Figure 7). Protein 
interaction analysis was carried out using the Interactome Analysis Workflow tool in 
Metacore, where significant interactions within sets were identified and used for 
subsequent Cytoscape network mapping and analysis. Cytoscape and KEGG pathway 
 46 
analysis revealed vemurafenib-treatment to drive an adhesion/RTK signaling network 
involving integrin α5β1, Src, paxillin, Talin and FAK (Figures 8-9).   
 
BRAF inhibitor-associated integrin/FN signaling is PTEN dependent 
Integrin-mediated adhesion signaling through the α5β1 receptor is typically induced 
following the binding of FN to the receptor. Therefore, we investigated whether the 
adhesion-modulated adaptive signaling identified through phospho-proteomics was the 
result of ECM remodeling. The BRAFV600E/PTEN- cohort of melanoma cell lines 
exhibited an increase in FN expression following vemurafenib treatment, where as the 
cell lines which are BRAFV600E/PTEN+ showed diminished FN expression following 
treatment (Figures 10-12). BRAF inhibition increased FN expression at both the mRNA 
and protein levels in the BRAFV600E/PTEN- cells (Figures 11-14), with ELISA assays 
showing the active secretion of protein into the cell culture media (Figure 13). These 
effects were not restricted to vemurafenib treatment and were reproduced with siRNA 
knockdown of BRAF (Figure 15) as well as following treatment with cytotoxic drugs such 
as cisplatin, carboplatin and paclitaxel (Figure 16).  No changes in other ECM proteins 
that are known to interact with α5β1 integrin (such as vitronectin) were noted (Figure 17). 
To explore the PTEN dependency of FN induction, we knocked down expression of 
PTEN using RNAi and utilized isogenic cell lines with a doxycycline-inducible form of 
PTEN. The siRNA-mediated knockdown of PTEN expression in WM164 cells 
(BRAFV600E/PTEN+) stimulated the production of FN in response to vemurafenib 
treatment, consistent with the phenotype observed in the PTEN- cohort (Figure 18). 
Conversely, induction of doxycycline-driven PTEN expression in WM793 cells 
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(BRAFV600E/PTEN-) resulted in a reduction of FN expression following vemurafenib 
treatment (Figures 19-20).  
 
Adhesion to FN limits apoptosis when BRAF is inhibited 
We next investigated whether increased FN expression observed in response to BRAF 
inhibition was required for therapeutic escape. Knockdown of FN using an siRNA pool, 
as well as by three individual siRNAs, significantly increased the sensitivity of these 
cells to vemurafenib, as observed by an increase in apoptosis (3 µM, 24 hrs) (Figures 
21-22). For these particular studies, cells were grown in 1% rather than 5% FBS to 
reduce the possible survival benefit from FN in the serum. The low serum levels 
increased basal levels of cell death particularly following treatment with the non-
targeting siRNA. The protective effects of FN up-regulation were mediated through 
integrin α5β1, with siRNA knockdown of α5 integrin leading to a significant increase in 
vemurafenib-induced apoptosis (Figure 23). The increased activity in AKT seen in 
response to BRAF inhibition is mediated through FN. Kinome array and Western blot 
studies showed siRNA knockdown of FN to abrogate the vemurafenib-mediated 
increases in AKT phosphorylation (Figures 24-25).  The increased PI3K/AKT signaling 
conferred a protective effect for the PTEN-cell lines. Combining the PI3K inhibitor GDC-
0941 with vemurafenib greatly enhanced vemurafenib-mediated apoptosis and led to a 
reduction of survival in long-term colony formation assays in PTEN- cell lines (Figures 
26-28). The combination of the PI3K inhibitor with vemurafenib did not induce a marked 
increase in apoptosis in PTEN+ cell lines as compared to PTEN- (Figure 28). Although 
increased STAT3 phosphorylation was observed following BRAF inhibition, its activity 
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was not dependent on FN expression (Figure 25). However, siRNA knock down of 
STAT3 was noted to partly suppress the FN up-regulation seen in response to BRAF 
inhibition (Figure 29).  
To understand the mechanism of apoptosis resistance, liquid chromatography multiple 
reaction monitoring (LC-MRM) was used to identify the BH3 family proteins required for 
FN-mediated survival (Figure 30) 142,150. These studies revealed Mcl-1 expression to be 
dependent upon signaling through α5 integrin and FN. siRNA knockdown of either α5 
integrin or FN led to a decrease in Mcl-1 expression when BRAF was inhibited (Figures 
30-32). The adhesion-mediated Mcl-1 expression was also dependent upon PI3K/AKT 
signaling with expression being reduced following treatment with the combination of 
vemurafenib and GDC0941 (Figure 33).  
 
FN expression correlates with PTEN expression in vivo and is increased in 
melanoma patients following vemurafenib treatment 
To test the in vivo relevance of our observations, we utilized a xenograft model where 
PTEN- and PTEN+ cell lines were subcutaneously injected into the flanks of SCID mice. 
Tumor-associated increases in FN staining and reduced BRAF inhibitor efficacy were 
observed in BRAFV600E/PTEN- but not BRAFV600E/PTEN+ melanoma tumors (Figures 
34-35). The BRAFV600E/PTEN- tumor xenografts were found to have basal FN 
expression (Figure 34), which may have resulted from the increased stress the cells 
experience under xenograft conditions. We demonstrated that mild acidosis (pH 6.7), 
such as that seen in vivo, was sufficient to induce FN expression in BRAFV600E/PTEN- 
cell lines in vitro (Figures 36-37). In some cases, xenografts remained on therapy until 
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resistance emerged. Resistant cell lines generated from xenografts chronically treated 
with the BRAF inhibitor showed elevated FN expression compared to the parental cell 
line controls, suggesting that the adaptive up-regulation of FN in response to therapy is 
a durable response (Figure 38).  
To establish the clinical significance of our findings, we analyzed an annotated tissue 
microarray (TMA) of 100 individual stage III/IV melanoma patient specimens (Tables 1-
3) for PTEN and FN expression. We found PTEN loss to be associated with a 
significantly reduced (P<0.05) overall survival (OS) (Figure 39). Furthermore, TMA 
analysis of patients with concurrent PTEN-/FNHigh expression revealed a trend towards 
reduced OS, with a median OS 15.1 months vs 45.2 months for PTEN-/FNhigh and 
PTEN+/FNLow, respectively (Figure 40).  Quantitative RT-PCR analysis of tumors from 4 
patients failing vemurafenib therapy identified increased intratumoral FN in two cases 
(Figure 41). Immunohistochemical (IHC) analysis of a second group of patient 
specimens (n=3) identified one tumor with higher FN expression in the post-BRAF 
inhibitor relapse sample that was absent in the initial specimen (Figure 42). We 
hypothesize that FN+ cells are able to persist in patients undergoing BRAF inhibitor 
therapy. One sample from a patient regressing on vemurafenib therapy showed a single 
viable cell surrounded by fibronectin, and another matched set of specimens showed 
increased FN+ melanoma cells upon progression (Figure 43). 
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FN-mediated adhesion signaling amplifies tumor-intrinsic and fibroblast-derived 
growth signals 
Integrin-mediated FN adhesion has been suggested to be critical for the maintenance of 
RTK signaling fidelity 139. In order to examine the relevance of adhesion signaling in 
tumor-autonomous therapeutic escape, we looked at global RTK tyrosine 
phosphorylation on RTK arrays in which melanoma cells were exposed to vemurafenib 
after a transfection with either non-targeting (NT) or FN siRNA. We observed an 
increase in the phosphorylation of EGFR, ERBB2, and ERBB3 following vemurafenib 
treatment and FN knockdown was able to abrogate the vemurafeninb-mediated 
increase in ERBB2 phosphorylation (Figure 44). Straussman et al have previously 
shown that fibroblast-derived HGF can weaken the sensitivity of melanoma cell lines to 
vemurafenib 121. Building on this, we noted that adhesion of melanoma cells to FN 
increased the efficiency of ligand-mediated RTK signaling. FN siRNA knockdown limited 
EGFR, c-MET and ERBB3 receptor phosphorylation, leading to impaired downstream 
AKT signaling (Figures 45-46). Meanwhile, knockdown of FN expression in 
BRAFV600E/PTEN+ cells did not lead to alterations in c-MET signaling (Figure 47).   
 
Vemurafenib treated PTEN- melanoma cells activate fibroblasts  
In addition to cell-autonomous survival-stimulating effects of FN upregulation, the ability 
of FN/integrin signaling to amplify fibroblast-derived growth factor signals through RTKs 
suggested a role for host cell co-option in therapeutic escape 151. Culture of fibroblasts 
with conditioned media from vemurafenib-treated melanoma cells led to differentiation 
of the fibroblasts characterized by increased FN and α-smooth muscle actin expression 
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(α-SMA), an effect parallel to stimulation of fibroblasts with exogenous TGF-β (Figure 
48). A link between BRAF inhibition and stromal activation was supported by the ability 
of vemurafenib to increase the expression and secretion of TGF-β from 
BRAFV600E/PTEN- melanoma cell lines (Figures 49-51). To determine the 
growth/survival benefits of activation and increase in FN expression we examined the 
effects of FN knockdown in two independent fibroblast cell lines. Knocking down FN 
expression significantly reduced fibroblast survival in the absence of serum (Figure 52). 
The ability of BRAFV600E/PTEN- melanoma cells to recruit and enhance fibroblast 
survival contributed to therapeutic escape of melanoma cells from vemurafenib 
treatment. Co-culture experiments validate that direct melanoma/fibroblast interaction 
can thwart the growth inhibitory effects of vemurafenib on melanoma cells (Figure 53).   
 
Crosstalk between host and tumor protect melanoma cells from vemurafenib-
mediated cytotoxicity through increased PI3K/AKT signaling 
It has previously been established that melanoma cells are capable of recruiting 
fibroblasts through secretion of TGF-β, and that fibroblasts can be a vital source of 
growth-stimulating ECM and growth factors 152,153. We show that the treatment of 3 
primary skin fibroblast cell lines with either TGF-β (0.1 and 1 pg/ml) or vemurafenib (3 
µM) leads to an increase in the release of NRG and HGF, respectively, suggesting that 
both melanoma and vemurafenib can stimulate priming of fibroblast-mediated 
microenvironment remodeling (Figures 54-56). However, we did not find vemurafenib to 
stimulate the release of NRG or TGF-β to induce expression of HGF from fibroblasts. 
For the first time, we present evidence of direct effects of vemurafenib on primary 
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human fibroblasts. We present that paradoxical MAPK activation through transactivation 
of CRAF is responsible for activating HGF release from fibroblasts upon vemurafenib 
treatment. Western blot analysis shows that treating fibroblasts with vemurafenib leads 
to increases in pERK and pCRAF. Alternatively, the combination of a MEK inhibitor 
trametinib with vemurafenib for vertical pathway inhibition blocked the paradoxical 
MAPK activation and HGF secretion (Figures 56-57).  Plating GFP-tagged melanoma 
cells onto primary human fibroblasts led to an amplification of pAKT signaling in the 
melanoma cells following vemurafenib treatment (Figures 58-59). We did not observe 
significant inhibition of AKT signaling melanoma/fibroblast co-cultures were treated with 
the combination of crizotinib or lapatinib with vemurafenib, or the triple combination 
(Figure 60), consistent with the observation that FN amplifies AKT signaling through 
multiple RTKs (Figure 44-46). Likewise, these combinations were not able to induce 
apoptosis in the melanoma cells (Figures 60). In contrast, combining vemurafenib with 
the PI3K inhibitor GDC0941 lead to a near-complete inhibition of the fibroblast-mediated 
AKT signaling in the melanoma cells, coupled with increased PARP cleavage (Figure 
60). Additional evidence for the function of PI3K in assisting fibroblast-mediated 
therapeutic resistance was established by significantly enhanced apoptosis following 
BRAF+PI3K inhibitor combination in 3 BRAFV600E/PTEN- melanoma cell lines (Figure 
61). The role of microenvironment-mediated PI3K/AKT signaling in therapeutic escape 
of BRAF/PTEN- mutant melanoma cells was demonstrated in animal xenograft models. 
Animals treated with the combination of the BRAF inhibitor PLX4720 and the PI3K 
inhibitor GDC-0941 caused substantial levels of tumor regression compared to either 
PLX4720 or GDC-0941 alone (Figures 62). In further support of BRAF+PI3K inhibitor 
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combination efficacy, when large, vehicle treated 1205Lu xenografts were switched to 
the vemurafenib/GDC combination, the tumors exhibited stabilization and regression. 
Likewise, when treatment was stopped in small, combination-treated 1205Lu xenografts 
this led to a dramatic acceleration of tumor growth (Figure 63). Consistent with the 
observation that the combination of a MEKi with a BRAFi leads to a reduction in side 
effects in patients112, the combination-treated mice showed very stable weights, 
whereas mice that were treated with either single inhibitor exhibited minor weight 
fluctuations  (Figure 64). A model showing the bi-directional signaling mechanism 
between the host and the melanoma cells under vemurafenib treatment is shown in 
Figure 65. 
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Figure 4. Work flow of the phospho-proteomics experiment. Experiment was 
performed on 3 individual BRAFV600E/PTEN- melanoma cell lines. 
 
 
 
Figure 5. Global overview of changes in tyrosine phosphorylation following 
vemurafenib treatment (3 µM, 24 hrs). The heatmap depicts relative intensity of 
tyrosine phosphorylated peptides in 3 melanoma cell lines following vemurafenib 
treatment, showing pronounced changes in some peptide phosphorylation levels and 
subtle changes in others. Relative intensities were calculated using MaxQuant analysis 
software based on the peak height for each peptide on the mass spectra. 
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Figure 6. Venn-diagram showing the overlap of tyrosine phosphorylated peptides 
following vemurafenib treatment. The experiment was performed on 3 individual 
melanoma cell lines (1205Lu, WM793, WM9), which were treated with vemurafenib (3 
µM, 24 hrs). Changes in phosphorylation of 57 peptides were common to all three cell 
lines.   
 
 
 
Figure 7. GeneGO pathway analysis. Phospho-proteomic data from Figures 2-3 was 
analyzed using the online GeneGO pathway analysis using Metacore. Among the 
pathways with significant alterations in tyrosine phosphorylations are cell adhesion, 
regulation of the cytoskeleton and RTK signaling. 
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Figure 8. Cytoscape network map of phosphorylation changes induced by BRAF 
inhibition. The phosphorylational changes induced by BRAF inhibition that were 
common to all three melanoma cell lines are depicted in a network, with degree of hub 
connectivity shown in increasing intensity of blue color. 
E F
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Figure 9. KEGG pathway map identifying the activation of integrin-mediated adhesion/RTK signaling following 
vemurafenib treatment. KEGG pathway mapping identified focal adhesion signaling pathway to be most altered 
following BRAF inhibition, based on the phosphor-proteomic analusis. Proteins identified to have changes in 
phosphorylation due to vemurafenib treatment depicted in pink.
F
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Figure 10. Basal levels of integrins and fibronectin in a panel of BRAFV600E 
PTEN+ and PTEN- cell lines. Western blot showing expression of PTEN, integrin αV, 
integrin α5, integrin β1 and FN in three BRAFV600E/PTEN+ melanoma cell lines (WM164, 
WM983A, 451Lu) and three that are BRAFV600E/PTEN- (1205Lu, WM793, WM9). Cell 
lines which are PTEN- show a marked increase in basal integrin α5 and integrin β1 
expression. GADPH shows even protein loading. 
 
 
 
Figure 11. Immunofluorescent staining shows vemurafenib to preferentially 
induce FN expression in BRAFV600E/PTEN- melanoma cell lines. 
Immunofluorescence staining showing the induction of FN expression (yellow) following 
48- and 72-hour 3µM vemurafenib treatment in three BRAFV600E/PTEN- melanoma cell 
lines. Vemurafenib treatment reduced FN expression in BRAFV600E/PTEN+ cell lines. 
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Figure 12. Western blot analysis shows vemurafenib to preferentially induce FN 
expression in BRAFV600E/PTEN- melanoma cell lines. Vemurafenib induces FN 
expression in BRAFV600E/PTEN- melanoma cell lines, and reduces its expression in 
BRAFV600E/PTEN+ cell lines. Western blot showing the induction of FN expression 
following 48- and 72-hour 3µM vemurafenib treatment. GADPH shows even protein 
loading. 
 
 
 
Figure 13. ELISA showing vemurafenib-mediated induction of fibronectin 
secretion. Media collected from 3 BRAFV600E/PTEN+ cell lines shows an increase in 
levels of secreted fibronectin as measured by an ELISA assay. 
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Figure 14. qRT-PCR showing vemurafenib-mediated induction of fibronectin  
mRNA expression.  qRT-PCR for FN1 was performed on the 1205Lu melanoma cell 
line. Data was normalized to GAPDH and 18S endogenous controls. 
 
 
 
Figure 15. Knockdown of BRAF induces FN expression in PTEN- cells. 
Immunofluorescence staining (left) and western blot analysis (right) show that siRNA-
mediated knockdown of BRAF leads to an increase in FN expression (yellow) in 1205Lu 
cells (PTEN-) and reduces expression in WM164 cells (PTEN+). GADPH shows even 
protein loading. 
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Figure 16. Cytotoxic chemotherapy induces FN expression in PTEN- melanoma 
cells. 1205Lu cells were treated with 10µM cisplatin, 1µM carboplatin and 3nM 
paclitaxel for 72 hours prior to being stained for FN (left, yellow) and analyzed by 
Western blot (right). GADPH shows even protein loading. 
 
 
 
Figure 17. Vemurafenib does not induce expression of vitronectin or laminin. 
1205Lu cells were treated with 3 µM vemurafenib for 0-8 hrs followed by western 
blotting for vitronectin, laminin, SNAIL and SLUG. GADPH shows even protein loading. 
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Figure 18. Vemurafenib-mediated fibronectin induction is PTEN dependent. 
Knockdown of PTEN leads to FN induction following BRAF inhibition. (left) western blot 
showing siRNA knockdown of PTEN in WM164 cells (PTEN+) leads to increased AKT 
signaling. (right) Immunofluorescence studies showing increased FN staining (yellow) 
following vemurarefnib treatment in cells with PTEN siRNA knockdown (3 µM, 48 hrs). 
 
 
 
Figure 19. Doxycycline-mediated induction of PTEN. The WM793TR (PTEN-) cell 
line with a doxycycline-inducible form of PTEN was stimulated with doxycycline (Dox) 
for 48 hours. Western blot shows the induction of PTEN to reduce AKT phosphorylation. 
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Figure 20. Induction of PTEN reduces FN expression following vemurafenib 
treatment. Following either induction or non-induction of PTEN, the WM793-TR cells 
were treated with vehicle or vemurafenib (3 µM, 2-48 hrs) and FN expression was 
measured by Western blot (top) and immunofluorescence (bottom). 
 
      
 
Figure 21. Induction of FN expression is required for drug resistance. 1205Lu 
melanoma cells were transfected with three individual siRNAs for FN followed by 
treatment with vemurafenib (3 µM, 72 hours).  Annexin V (left) and TMRM (right) 
staining was analyzed by flow cytometry. siRNA knockdown of FN enhances 
vemurafenib-mediated cell death. 
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Figure 22. Knockdown of FN enhances vemurafenib-mediated caspase cleavage. 
WM793 and WM9 cells were transfected with either non-targeting or FN siRNA prior to 
treatment with vemurafenib (3 µM, 24 hours). Western blot shows levels of FN, cleaved 
caspase-7 (cCaspase) and GAPDH. 
 
      
 
Figure 23. Knockdown of α5 or β1 integrins enhances vemurafenib-mediated cell 
death. 1205Lu melanoma cells were transfected with two individual siRNAs for α5 or β1 
integrins followed by treatment with vemurafenib (3 µM, 48 hours).  Annexin V (left) and 
TMRM (right) staining was analyzed by flow cytometry. 
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Figure 24. FN knockdown attenuates vemurafenib-mediated AKT signaling. (left) 
Kinome array demonstrating levels of AKT phosphprylated at serine 473 following 
vemurafenib treatment in the presence of siRNA-mediated FN knockdown (3 µM, 8 hrs). 
(right) Quantification of pAKT densitometry on the kinome array. 
 
 
 
Figure 25. FN knockdown prevents adaptive AKT signaling following BRAF 
inhibition. Western blot confirmation of the kinome array from Figure 21 demonstrating 
that FN knockdown blocks increase in pAKT following BRAF inhibition (3 µM, 8 hrs). 
Quantification of pAKT levels was carried out using densitometry analysis. 
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Figure 26. Inhibition of PI3K/AKT signaling in combination with BRAF inhibition 
enhances cytotoxicity in PTEN- melanoma cell lines. Treatment with vemurafenib (3 
µM) + GDC-0941 (3 µM) induces significantly more apoptosis compared to either 
inhibitor alone. Cells were treated with the stated drug combinations for 48 hrs followed 
by Annexin-V  (left) and TMRM (right) staining and analysis by flow cytometry. 
 
 
 
Figure 27. Combined BRAF/PI3K inhibition is associated with prolonged 
suppression of cell growth. Three BRAFV600E/PTEN- melanoma cell lines were 
treated with 3 µM vemurafenib and 3 µM GDC-0941 for 2 weeks. Colonies were 
visualized following staining with crystal violet. 
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Figure 28. Inhibition of PI3K/AKT signaling in combination with BRAF inhibition 
had very minor effects on PTEN+ melanoma cell line survival. Treatment with 
vemurafenib (3 µM) + GDC-0941 (3 µM) has little effect on apoptosis beyond 
vemurafenib alone in WM164 PTEN+ cell line compared to 1205Lu PTEN- cell line. 
Cells were treated with the stated drug combinations for 48 hrs followed by Annexin-V 
and TMRM staining and analysis by flow cytometry. 
 
 
 
Figure 29. STAT3 signaling regulates fibronectin responses following 
vemurafenib treatment. 1205Lu melanoma cells were transfected with STAT3 siRNA 
and treated with vemurafenib (3 µM, 8 hrs). Western blot analysis for STAT3 and 
fibronectin shows an increase in STAT3 and fibronectin in response to vemurafenib 
treatment, with fibronectin upregulation being reduced following STAT3 knockdown. 
GAPDH shows even protein loading. 
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Figure 30. α5 integrin is required for maintenance of Mcl-1 expression following 
BRAF inhibition. LC-MRM experiment showing the absolute fold changes in 11 BH3 
family proteins following siRNA knockdown of α5 integrin +/- 3 µM vemurafenib 
treatment. 
 
    
 
Figure 31. Integrin α5 is critical for the regulation of Mcl-1 expression. Western 
blot showing siRNA knockdown of integrin α5 and β1 in combination with 3 µM 
vemurafenib treatment. Mcl-1 expression decreases in the presence of vemurafenib 
when integrin α5 in knocked down. 
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Figure 32. Knockdown of FN is associated with decreased Mcl-1 expression 
following vemurafenib treatment. 1205Lu cell line was transfected with fibronectin 
siRNA, and then subjected to vemurafenib treatment (3 µM, 72 hours). Western blot 
analysis shows expression of fibronectin and Mcl-1. GAPDH shows even protein 
loading. 
 
 
 
Figure 33. Combined treatment with a BRAF and PI3K inhibitor downregulates 
Mcl-1 expression. 1205Lu, WM793 and WM9 cells were treated with either 3 µM 
vemurafenib, 3 µM PI3K inhibitor (GDC-0941) or a combination of both for 72 hours 
followed by Western blotting for Mcl-1. GAPDH shows even protein loading. 
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Figure 34.  Vemurafenib induces FN expression in human melanoma mouse 
xenograft models. FN expression is induced in BRAFV600E/PTEN- (1205Lu) but not 
BRAFV600E/PTEN+ (WM164) human melanoma mouse xenografts following 
vemurafenib treatment. Tumors were allowed to grow until palpable, after which time 
mice received control chow or chow containing PLX4720 (417mg/kg). Tumors were 
fixed and embedded in paraffin blocks, then stained by IHC for S100 and FN. 
 
 
 
Figure 35. Vemurafenib has greater anti-proliferative effects on BRAFV600E/PTEN+ 
rather than BRAFV600E/PTEN- human melanoma xenografts. Tumor volume was 
measured using calipers over a period of two weeks, and reduction in tumor growth was 
compared by calculating the fold-decrease in tumor volume (tumor volume = ½ x L x 
W2). 
 
A
PTEN4 PTEN+
C
on
tro
l
26
$D
ay
s
42
$D
ay
s
Fibronectin S100 Fibronectin S100
p = 0.0122
0 2 4 6 8 10 12 14
0
1
2
3
4
PTEN+
PTEN4
Re
du
ct
io
n$
in
$tu
m
or
$g
ro
wt
h
wi
th
$$4
17
$m
g/
kg
$P
LX
47
20
$c
ho
w
Days$Post$Treatment
 71 
 
 
Figure 36. Western blot showing acid stress induced FN expression in 
BRAFV600E/PTEN- melanoma cell lines. 1205Lu melanoma cell line was grown in 
either normal (pH 7.4) or mildly acidic (pH 6.7) media for 8-72 hours and Western 
blotting was used to show increased FN expression in cells cultured in mildly acidic 
media. 
 
 
 
Figure 37. Immunofluorescent staining confirms acid stress induced FN 
expression in BRAFV600E/PTEN- melanoma cell lines. 1205Lu melanoma cell line 
was grown in either normal (pH 7.4) or mildly acidic (pH 6.7) media for 8-72 hours. 
Immunofluorescent staining was used to show increased FN expression (yellow) 
following treatment with mildly acidic media as in Figure 32.  
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Figure 38. Melanoma cell lines with acquired vemurafenib resistance show 
increased FN expression. 1205Lu cells were xenografted into SCID mice and treated 
chronically with the BRAF inhibitor PLX4720- formulated chow until resistance emerged. 
Two cells lines 1205LuXR and 1205LuXR2 were generated from the resistant tumors. 
Western blot analysis shows elevated expression of FN in cell lines generated from 
resistant tumors. GAPDH shows even protein loading. 
 
Table 1.  Patient demographics for the specimens on the annotated melanoma TMA. 
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Table 2. Median overall survival data for melanoma patients represented on the TMA 
based upon PTEN staining status. 
 
 
 
Table 3. Median overall survival data for melanoma patients represented on the TMA 
based upon PTEN and FN staining status. 
 
Status 
Event 
Rate 
Median Survival 
(months) 95% CI (months) 
FN low / PTEN- 5/8 28.3 0.4-56.2 
FN high / PTEN- 19/26 15.1 10.8-19.4 
FN low / PTEN+ 6/17 45.2 0.1-90.3 
FN high / PTEN+ 23/41 29.9 12.8-47.0 
Overall 53/92 23.0 11.3-34.7 
 
 
 
Figure 39. Lack of PTEN expression predicts for worse overall survival in 
melanoma patients. Overall survival curve for a cohort of melanoma patients (n=93). 
Staining intensity was scored by the dermatopathologist as follows: absent staining=0, 
weak staining=1, moderate staining=2, strong staining =3. All tumor cells in the infiltrate 
showed diffuse, uniform staining. PTEN dichotomous scoring was assigned as absent 
(IHC=0) versus present (IHC=1-3).  
Status
Event*
Rate
Median*
Survival*
(months)
95%*CI*
(months)
PTEN> 24/34 16.8 10.9>22.7
PTEN+ 29/59 40.0 23.7>56.3
Overall 53/93 23.0 7.8>38.2
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Figure 40. Lack of PTEN expression and high FN expression predicts for worse 
overall survival in melanoma patients. (Left) Representative FN IHC staining on the 
tissue microarray. (Right) Overall survival curve for a cohort of melanoma patients 
(n=92). Staining intensity was scored by the dermatopathologist as follows: absent 
staining=0, weak staining=1, moderate staining=2, strong staining =3. All tumor cells in 
the infiltrate showed diffuse, uniform staining. Dichotomous high and low FN levels were 
assigned based on IHC scores of 0-1 and 2-3, respectively.  
 
 
 
Figure 41. Some melanoma patients failing BRAF inhibitor therapy show 
increased intratumoral FN mRNA expression. Data shows q-RT-PCR experiments 
on 4 matched (pre and post treatment) pairs of melanoma patient specimens receiving 
vemurafenib therapy (960 mg BID). 
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Figure 42. Increased FN staining in a melanoma specimen from a patient failing 
vemurafenib therapy. Data show IHC staining for FN pre- and post-vemurafenib 
treatment (960 mg BID). 
 
 
 
Figure 43. Rare viable FN+ melanoma cells within lesions are selected for during 
vemurafenib therapy. (Top) IHC image of a regressing melanoma specimen, pink 
staining shows FN. Brown is melanin. Arrow indicates a viable cell surrounded by 
fibronectin. (Bottom) Immunohistochemical (IHC) analysis of fibronectin (red) in 
specimens from a single patient collected prior to treatment and after clinical 
progression on vemurafenib treatment. 
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Figure 44. Adhesion to FN amplifies RTK signals in melanoma BRAFV600E/PTEN- 
cells. RTK arrays identify vemurafenib-mediated ERBB2 signaling as being dependent 
on FN-mediated adhesion. (left) 1205Lu melanoma cells were treated with either non-
targeting (NT) or FN (FN) specific siRNAs prior to treatment with vemurafenib (3µM, 24 
hrs). Knockdown of FN reduces basal levels of ERBB2 and ERBB3 phosphorylation and 
limits vemurafenib-induced ERBB2 signaling. (right) Quantification of pEGFR, pERBB2 
and pERBB3 densitometry on the RTK array. 
 
 
 
Figure 45. Adhesion to FN is required for maintaining the fidelity of exogenous 
RTK signals in 1205Lu (PTEN-). Western blot analysis is used to demonstrate that 
siRNA knockdown impairs responses to exogenous HGF, EGF and NRG. 1205Lu cells 
were treated with either non-targeting (NT) or FN (FN) siRNA prior to stimulation with 
HGF, EGF or NRG (25ng/ml, 100ng/ml and 50ng/ml respectively). Knockdown of FN 
expression reduces the magnitude of AKT signaling following HGF, EGF and NRG-1 
treatment and ERK signaling following EGF and NRG-1 treatment. 
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Figure 46. Adhesion to FN is required for maintaining the fidelity of exogenous 
RTK signals in WM9 (PTEN-). WM9 cells were treated with either non-targeting (NT) or 
FN (FN) siRNA prior to stimulation with HGF, EGF or NRG (25ng/ml, 100ng/ml and 
50ng/ml respectively). Western blot analysis is used to demonstrate that knockdown of 
FN expression reduces the magnitude of AKT signaling following HGF, EGF and NRG-1 
treatments. 
 
 
 
Figure 47. Knockdown of FN expression does not affect AKT signaling following 
HGF stimulation in WM164 (PTEN+). WM164 cells were treated with either non-
targeting (NT) or FN (FN) siRNA prior to stimulation with 25ng/ml HGF. Western blot 
analysis is used to demonstrate that knockdown of FN expression did not alter levels of 
pAKT following HGF stimulation. 
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Figure 48. BRAFV600E/PTEN- cells and vemurafenib induce the differentiation and 
activation of host fibroblasts. Conditioned media from vemurafenib-treated 
melanoma cells and exogenous TGF-β induces the differentiation of human primary 
skin fibroblasts. FF2447 fibroblasts were treated with either conditioned media from 
1205Lu cells (CM), conditioned media from 1205Lu cells treated with vemurafenib for 
48 hours (CM+vemu) or 12.5pg/ml exogenous TGF-β1 (TGFβ1) for 48 hours before 
being fixed and stained for FN (FN, yellow) and α-smooth muscle actin (α-SMA, red) 
(top). Images of staining were analyzed using Definiens® Developer v2.0 (Definiens 
AG, Munich, Germany) software suite, total fluorescence intensity per nuclei was 
quantified (bottom). 
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Figure 49. Western blot shows vemurafenib-mediated induction of TGF-β 
expression. Western blot  assay was performed on three BRAFV600E/PTEN- and three 
BRAFV600E/PTEN+ cell lines. Data shows the expression of TGF-β to increase in 
BRAFV600E/PTEN- cell lines but not in BRAFV600E/PTEN+ cell lines  following 3µM 
vemurafenib treatment. 
 
 
 
Figure 50. ELISA shows vemurafenib-mediated induction of TGF-β secretion. 
ELISA assay was performed on three BRAFV600E/PTEN- and three BRAFV600E/PTEN+ 
cell lines. Data shows the induction of TGF-β release from BRAFV600E/PTEN- cell lines 
but not in BRAFV600E/PTEN+ cell lines, expressed in pg/ml fold changes with 3µM 
vemurafenib (72 hours). 
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Figure 51. Immunofluorescence staining shows vemurafenib-mediated induction 
of TGF-β expression. 1205Lu melanoma cell line was treated with vemurafenib (1-10 
µM) for 72 hours. After this time cells were fixed and stained for TGF-β (yellow), nuclei 
(DAPI, Blue) and phalloidin (red). 
 
 
 
Figure 52. FN is required for optimal growth and survival of human primary skin 
fibroblasts under stress-inducing conditions. FF2507 primary skin fibroblasts were 
treated with either non-targeting (NT) or FN (FN) siRNA prior to serum starvation 
(72hours). Cell viability was assessed using Alamar Blue assay, and percentage of 
growth inhibition was normalized to the NT control. 
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Figure 53. Fibroblasts protect melanoma cells from vemurafenib mediated growth 
inhibition. (Top) GFP-tagged 1205Lu melanoma cells were plated on either tissue 
culture plastic or confluent monolayers of FF2504 fibroblasts and treated with 
vemurafenib (3µM, 72 hrs). (Bottom) cell counts were carried out on three fields-of-view 
(FOV) per treatment, experiment was repeated in triplicate. 
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Figure 54. TGF-β induces NRG release from fibroblasts. ELISA data showing NRG 
release from 3 human skin fibroblast cell lines, following treatment with TGF-β (100 pg 
and 1 ng/ml) for 72 hours. 
 
 
 
Figure 55. Vemurafenib increases HGF release from fibroblasts. ELISA data 
showing HGF release from 3 human skin fibroblast cell lines, following treatment with 
vemurafenib (3 µM, 72 hrs). 
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Figure 56. Trametinib blocks vemurafenib-induced HGF release from fibroblasts. 
ELISA data showing HGF release from 3 human skin fibroblast cell lines, following 
treatment with vemurafenib (3 µM, 72 hrs). 
 
 
 
Figure 57. Trametinib blocks vemurafenib-induced paradoxical MAPK activation 
from fibroblasts. Western blot showing the paradoxical ERK activation in FF2507 
human skin fibroblast cell line following treatment with vemurafenib (3 µM, 72 hrs). 
 
 
Co
ntr
ol
Ve
mu
raf
en
ib
Tr
am
eti
nib
Ve
m 
+ T
ra
0
50
100
150
200
pg
/m
l H
G
F 
pe
r 1
.0
x1
06
 c
el
ls
 
Co
ntr
ol
Ve
mu
raf
en
ib
Tr
am
eti
nib
Ve
m 
+ T
ra
0
100
200
300
pg
/m
l H
G
F 
pe
r 1
.0
x1
06
 c
el
ls
FF2504 FF2507
* *
pERK
C
on
tro
l
3&
M
$v
em
u


!

ve
m
u$
+$
tra
m
FF2507
ERK
GAPDH
H
 84 
 
 
Figure 58. Co-culture of melanoma cells on top of fibroblasts is associated with 
increased AKT signaling that can be enhanced following vemurafenib treatment.  
GFP-tagged WM9 melanoma cells were plated on either tissue culture plastic or on top 
of confluent monolayers of FF2507 fibroblasts before being treated with vehicle or 3µM 
vemurafenib for 24 hours. Cultures were then fixed and stained for phospho-AKT 
(Ser473: Red). 
 
 
 
Figure 59. Quantification of pAKT amplification in melanoma cells plated on 
fibroblasts following vemurafenib treatment. GFP-tagged WM9 melanoma cells 
were plated on either tissue culture plastic or on top of confluent monolayers of 
fibroblasts (FF2504, FF2507, FF2447) before being treated with vehicle or 3µM 
vemurafenib for 24 hrs. Cultures were then fixed and stained for phospho-AKT 
(Ser473). Images were analyzed using Definiens® Developer v2.0 (Definiens AG, 
Munich, Germany) software suite, total fluorescence intensity per GFP-positive cell was 
quantified. Fold changes in vemurafenib-induced phospho-AKT were calculated, 
comparing the group plated on plastic to those plated on three individual primary human 
skin fibroblast cultures. 
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Figure 60. Sensitivity of PTEN- melanoma cells to vemurafenib is AKT-dependent. 
GFP-tagged WM9 melanoma cells were plated on either tissue culture plastic or on top 
of a confluent monolayer of FF2504 fibroblasts prior to being treated with single agent 
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Figure 60 Continued. or different combinations of 3 µM vemurafenib (BRAFi), 3 µM 
GDC-0941 (PI3Ki), 200 nM crizotinib (METi), and 1 µM lapatinib (HER2i). Analysis of 
phospho-AKT (Ser473) and cleaved PARP on individual GFP-tagged cells was 
performed using flow cytometry. Cells that contained low levels of AKT and high levels 
cleaved PARP were outlined on pseudo-colored dot plots, showing percent of cells 
compared to the whole GFP+ population. Histograms show the levels of phospho-AKT, 
with an AKT+ gate drawn based on 3µM GDC-0941 treatment on plastic. Column 
graphs show the percentage of melanoma cells that are in the AKT+ and cleaved 
PARP+ populations. 
 
 
 
Figure 61. The combination of a BRAF and a PI3K/AKT inhibitor reverses 
fibroblast-mediated protection from vemurafenib. GFP-tagged melanoma cells 
(WM793, 1205Lu) were seeded on top of fibroblast cell lines (FF2504, FF2507, 
FF2447) overnight before being treated with either vehicle control or 3µM vemurafenib 
and 3µM GDC0941 for 72 hrs before being stained for annexin-V and analyzed by flow 
cytometry. P-values were calculated between vemurafenib only and 
vemurafenib/GDC0941 combination treatments. 
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Figure 62. The combination of PLX-4720 and GDC-0941 in vivo causes significant 
levels of tumor regression compared to either PLX4720 or GDC-0941 alone in 
BRAFV600E PTEN- xenografts. Tumors were grown until palpable, after which time 
mice received control chow, chow containing PLX4720 (417mg/kg), vehicle oral gavage, 
or GDC-0941 via oral gavage (150mg/kg) (16 xenografts per treatment group). Tumors 
were measured using calipers, and tumor volume was calculated using the modified 
ellipsoid formula (tumor volume = ½ x L x W2). p-values were calculated between 
control and treatment groups on day 10 (top). Tumor weights were measured upon 
resection at the point of treatment termination for each mouse (bottom). 
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Figure 63. Switching of treatment groups shows a reciprocal effect. Switching of 
large, vehicle-treated 1205Lu xenografts to the PLX4720/GDC combination leads to 
tumor stabilization and regression (left). Four xenografts were switched from control to 
PLX4720/GDC combination on day 11. Switching of small, combination-treated 1205Lu 
xenografts to vehicle control treatment leads to dramatic acceleration in tumor growth 
(right). Three xenografts were switched from control to PLX4720/GDC combination on 
day 22. 
 
 
 
 
Figure 64. Combination treatment promotes stable mouse weight maintenance. 
The combination of PLX-4720 and GDC-0941 in vivo causes smaller fluctuation in 
mouse weight compared to either PLX-4720 or GDC-0941 alone. Mice were weighted 
every other day for the duration of the study. 
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Figure 65. A model showing the interaction of the host/melanoma cells under 
vemurafenib treatment. Upon vemurafenib treatment, the PTEN- melanoma cells 
upregulate the production and secretion of fibronectin, activating signaling through 
integrin α5β1. Additionally, the PTEN- melanoma cells are stimulated to secrete TGF-
β1. Vemurafenib-induced paradoxical MAPK activation as well as paracrine TGF-β1 
signaling activates the stromal fibroblasts to secrete additional ECM and release growth 
factors such as HGF and NRG-1. Due to activated integrins, the melanoma cells are 
able to amplify growth factor-mediated signals through RTKs, leading to downstream 
PI3K/AKT activation and ultimately increased survival signaling. Meanwhile, PTEN+ 
melanoma cells do not exhibit an increase in FN or TGF-β1 expression or secretion in 
response to vemurafenib and are basally sensitive to vemurafenib treatment. 
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CHAPTER IV: 
DISCUSSION Metastatic	   melanoma	   is	   a	   disease	   that	   can	   rapidly	   adapt	   to	   virtually	   every	   attempted	  treatment	   strategy,	  with	  a	   significant	  number	  of	  mechanisms	   for	   therapeutic	  escape.	  The	  heterogeneity	   in	   melanoma	   signaling	   has	   made	   it	   a	   great	   challenge	   to	   understand	   the	  process	  of	  adaptation.	  A	  number	  of	  subtle	  alterations	   in	   levels	  of	  signaling	  molecules	  and	  RTKs	   have	   been	   shown	   to	   confer	   resistance	   to	  BRAF	   and	  MEK	   inhibitors	   (e.g.	   cyclin	  D1,	  COT,	   BRAF,	   CRAF,	  MEK1	  mutations,	   PDGFR,	   IGF1R)	   (reviewed	   in	   154).	   The	   current	  work	  utilized	  comprehensive	  phospho-­‐proteomic	  analyses	   to	  characterize	  a	  unique	  mechanism	  of	  BRAF	   inhibitor	   resistance	  mediated	   through	   remodeling	  of	   the	  microenvironment	  and	  bi-­‐directional	   signaling	  between	  melanoma	   cells	   and	  host	   fibroblasts.	  Knowing	   that	   even	  one	  melanoma	  cell	  can	  establish	  new	  tumors	  in	  vivo	  155,	  it	  is	  of	  major	  clinical	  significance	  if	  the	  healthy	  host	  cells	  are	  capable	  of	  providing	  or	  enhancing	  the	  protection	  for	  even	  a	  small	  number	  of	  melanoma	  cells.	  We	  used	  phosphoproteomic	  analysis	  on	  a	  group	  of	  BRAFV600E/PTEN-­‐	  melanoma	  cell	  lines	  to	  establish	   that	   vemurafenib	   treatment	   can	   lead	   to	   adaptive	   signaling	   through	   proteins	  implicated	   in	   EMT,	   α5β1	   integrin,	   FN,	   focal	   adhesion	   kinase	   (FAK),	   Src,	   paxillin,	   talin	   and	  TGF-­‐β	   156.	   EMT	   has	   been	  most	   thoroughly	   described	   in	   the	   oncogenic	   transformation	   of	  epithelial	  cells,	  marked	  by	  an	  increase	  in	  motility,	  upregulated	  expression	  of	  the	  ECM	  (such	  as	  FN),	  and	  drug	  resistance	  156.	  Although	  melanocytes	  are	  actually	  derived	  from	  the	  neural	  crest	   and	   are	   not	   epithelial	   in	   origin,	   an	   EMT-­‐like	   state	   has	   been	   observed	   with	   the	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introduction	  of	  mutant	  BRAF	   157-­‐159.	   	   In	   this	  work,	  we	  present	  novel	  evidence	  showing	  an	  EMT-­‐like	   phenotype	   shift	   with	   BRAF	   inhibitor	   treatment	   in	   melanoma	   cells	   that	   lack	   a	  functional	  form	  of	  PTEN.	  An	  EMT	  switch	  mediated	  through	  loss	  of	  PTEN	  and	  increased	  AKT	  signaling	  has	  been	  shown	  in	  various	  epithelial	  tumor	  types	  including	  prostate	  cancer	  and	  nasopharyngeal	   tumors	   160-­‐162.	   	   We	   have	   found	   that	   BRAFV600E/PTEN-­‐	   melanoma	   cells	  exhibit	   a	   vemurafenib-­‐induced	   EMT	   through	   an	   increase	   in	   FN/α5β1	   integrin	   signaling.	  These	  EMT	  responses	  were	  also	  recapitulated	  through	  cytotoxic	  chemotherapeutic	  drugs,	  suggesting	  this	  phenotype	  switch	  to	  be	  a	  more	  generalized	  stress	  response	  allowing	  these	  cells	   a	   greater	   fitness	   to	  withstand	  harsh	   environmental	   changes.	  Mild	   acidosis	   (pH	  6.7),	  another	   cancer-­‐relevant	   form	   of	   stress,	   also	   elicited	   an	   increase	   FN	   expression	   in	   the	  BRAFV600E/PTEN-­‐	  melanoma	  cells.	  The	  relationship	  between	  PTEN	  loss	  and	  FN	  expression	  has	  previously	  been	  described	  in	  pathological	  fibrotic	  states	  such	  as	  pulmonary	  fibrosis.	  In	  pulmonary	   fibrosis,	  PTEN	  downregulation	   in	   infiltrating	   fibroblasts	  results	   in	  an	   increase	  of	   FN	   deposition	   163,164.	   Here,	   we	   present	   a	   link	   between	   PTEN/FN	   status	   and	   clinical	  prognosis.	   TMA	   analysis	   illustrated	   that	   decreased	   PTEN	   expression	   significantly	  correlated	   with	   worse	   overall	   survival.	   When	   FN	   expression	   was	   added	   to	   the	   analysis,	  patients	  whose	  tumors	  presented	  high	  FN	  expression	  coupled	  with	  a	  loss	  of	  PTEN	  showed	  a	  trend	  towards	  poorer	  overall	  survival	  than	  those	  whose	  tumors	  were	  PTEN	  high/FN	  low	  (15.1	  vs	  45.2	  months,	  median	  OS).	  	  Similarly,	   the	   in	  vitro	  studies	  demonstrated	  that	  the	   induction	  of	   integrin/FN	  signaling	   in	  PTEN-­‐	  melanoma	  cell	  lines	  conferred	  resistance	  from	  the	  cytotoxic	  effects	  of	  vemurafenib.	  To	   explain	   the	   mechanism	   behind	   integrin-­‐mediated	   control	   of	   apoptosis,	   we	   found	  integrin	   α5	   signaling	   to	   be	   required	   for	   maintenance	   of	   Mcl-­‐1	   expression,	   a	   vital	   anti-­‐
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apoptotic	  signaling	  modulator	  that	  binds	  to	  BIM-­‐EL	  and	  inhibits	  the	  activity	  of	  pro-­‐apoptotic	  Bak/Bax	  165,166.	  The	  expression	  of	  Mcl-­‐1	  can	  be	  regulated	  at	  multiple	  levels.	  PI3K/AKT	  has	  been	  shown	  to	  control	   the	  transcription	  of	  Mcl-­‐1	  and	   its	  proteasomal	  degradation	  can	  be	  blocked	   via	  MEK-­‐mediated	   phosphorylation	   of	  Mcl-­‐1	   165,167.	   	  We	   observed	   a	   decrease	   in	  AKT	   activity	   following	   FN	   knockdown	   and	   downregulation	   of	  Mcl-­‐1	   expression	  with	   the	  combination	   of	   BRAF/PI3K	   inhibitors,	   supporting	   a	   role	   for	   PI3K/AKT	   pathway	   in	   the	  integrin-­‐mediated	  maintenance	  of	  Mcl-­‐1.	  Previous	   studies	   have	   shown	   that	   attachment	   to	   the	   appropriate	   ECM	   is	   critical	   for	  fibroblast	  survival,	  and	   that	  adhesion	   to	  FN	  can	  constitute	  a	  key	  survival	   signal	   151,168-­‐170.	  Additionally,	  FN	  is	  a	  strong	  chemo-­‐attractant	  for	  fibroblasts,	  stimulating	  their	  motility	  171.	  Here	   we	   present	   evidence	   for	   fibroblast	   activation	   and	   recruitment	   through	   the	  expression/secretion	  of	  FN,	  as	  well	  as	   the	  release	  of	  TGF-­‐β,	   from	  melanoma	  cells	   treated	  with	  a	  BRAF	   inhibitor	   is	   critical	   for	   the	   recruitment	  and	  maintenance	  of	  host	   fibroblasts.	  Treatment	   of	   fibroblasts	   with	   either	   exogenous	   TGF-­‐β	   or	   conditioned	   media	   from	  vemurafenib-­‐treated	   melanoma	   cells	   led	   to	   fibroblast	   activation	   and	   differentiation,	  marked	   by	   an	   increases	   in	   α-­‐smooth	  muscle	   actin	   and	   fibronectin	   expression	   as	  well	   as	  NRG	   and	   HGF	   release.	   The	   ability	   of	   vemurafenib	   to	   stimulate	   normal	   primary	   skin	  fibroblasts	   to	   release	  HGF	   is	   an	   unexpected,	   novel	   finding.	   Although	   vemurafenib-­‐driven	  paradoxical	   MAPK	   activation	   in	   cells	   with	   RAS	   mutations	   or	   upstream	   RTK	   activity	   has	  been	  shown	  previously,	  paradoxical	  MAPK	  signaling	  in	  normal	  human	  fibroblasts	  has	  never	  been	  described	  172.	  	  	  The	   ability	   of	   drug-­‐treated	   melanoma	   cells	   to	   stimulate	   an	   increase	   in	   NRG	   and	   HGF	  secretion	   from	   fibroblasts	   was	   suggestive	   of	   a	   role	   for	   host	   cells	   in	   facilitating	   BRAF	  
 93 
inhibitor	   resistance.	  One	  study	  shows	   that	  BRAF-­‐mutant	  melanoma	  cells	   typically	  display	  high	   levels	   of	   feedback	   inhibition	   in	   the	  MAPK	   signaling	   pathway	   blocking	   the	   ability	   of	  RTKs	  to	  activate	  downstream	  signaling	  modulators	  in	  the	  MAPK	  pathway	  122.	  Inhibitors	  of	  BRAF	   are	   shown	   to	   relieve	   this	   feedback	   inhibition,	   leading	   to	   higher	   responsiveness	   to	  growth	   factors	   such	   as	   EGF,	  NRG,	  HGF	   and	   fibroblast	   growth	   factor	   (FGF)	   122.	   A	   number	  studies	   have	   already	   confirmed	   that	  HGF	   and	  NRG	   can	   limit	   the	   sensitivity	   of	  melanoma	  cells	  to	  vemurafenib	  and	  its	  analogue	  PLX4720	  106,120,121.	  	  	  In	  our	  work,	  the	  expression	  of	  FN	  was	  required	  for	  maximum	  PI3K/AKT	  signaling	  activation	  in	  response	  to	  exogenous	  HGF,	  NRG	  and	  EGF,	  proving	  environmental	  remodeling	  to	  have	  a	  pivotal	  role	  in	  the	  magnification	  of	  GF-­‐mediated	  resistance	  signaling.	  	  The	  role	  of	  integrin	  and	  RTK	  signaling	  cooperation	  for	  downstream	  PI3K/AKT	  pathway	   activation	   has	   been	  demonstrated	   in	   lung	   cancer	   173,139.	  Similarly,	   the	   crucial	   role	   of	   α5β1	   integrin	   in	   RTK	   signaling	   efficiency	   has	   been	  demonstrated	  for	  VEGFR3	  receptor	  in	  lymphatic	  vessels	  and	  EGFR	  and	  ERBB3	  in	  intestinal	  epithelial	  cells	  173,174.	  In	  other	  studies,	  integrin	  α5β1	  has	  been	  shown	  to	  form	  a	  complex	  with	  c-­‐MET,	   leading	   to	   a	   greater	   level	   of	   MET	   phosphorylation	   in	   the	   presence	   of	   either	  vitronectin	  or	  FN	  175.	  	  Host-­‐mediated	   drug	   resistance	   has	   been	   described	   in	   multiple	   myeloma,	   where	   β1-­‐integrin-­‐mediated	   was	   shown	   to	   amplify	   IL-­‐6-­‐driven	   STAT3	   coupled	   with	   increased	  expression	  of	  Bcl-­‐XL	  and	  decreased	  BIM	  expression	  176.	  ECM-­‐mediated	  protection	  has	  also	  been	   explored	   in	  NSCLC	   and	   ovarian	   cancer,	  where	   the	   protective	   effects	  were	   achieved	  through	   binding	   to	   laminin	   and	   collagen	   IV,	   respectively	   177,178.	   Our	   own	   work	   has	  demonstrated	   that	   attachment	   of	   melanoma	   cells	   to	   fibroblasts	   greatly	   enhanced	   AKT	  signaling	  in	  the	  melanoma	  cells,	  an	  effect	  mediated	  through	  multiple	  RTKs.	  We	  show	  that	  
 94 
the	   BRAF/PI3K	   inhibitor	   combination	   was	   much	   more	   potent	   at	   overcoming	   the	  microenvironment-­‐driven	  adaptive	  survival	  signaling	  than	  a	  BRAF	  inhibitor	  combined	  with	  multiple	  RTK	  inhibitors	  (model	  shown	  in	  Figure	  8).	  	  The	  dependence	  on	  PI3K	  signaling	  in	  microenvironment-­‐mediated	  therapeutic	  adaption	  was	  further	  confirmed	  by	  the	  ability	  of	  combined	   BRAF/PI3K	   inhibition	   to	   achieve	   tumor	   regression	   without	   significant	   side-­‐effects	   in	   a	   xenograft	  mouse	  model.	  Taken	   together,	   these	  data	   suggest	   a	   crucial	   role	   for	  PI3K/AKT	   signaling	   in	   integrating	   several	   host-­‐derived	   signals	   driving	   the	   therapeutic	  escape.	  Long-­‐term	  success	  of	  targeted	  small	  molecule	  therapies	  for	  treatment	  of	  metastatic	  melanoma	   patients	   will	   largely	   depend	   on	   the	   ability	   of	   rational	   drug	   combinations	   to	  overcome	   or	   delay	   the	   therapeutic	   adaption	   in	   the	   escaping	   population	   of	   cells	   that	  eventually	  repopulate	  the	  tumor.	  This	  work	  presents	  new	  evidence	  that	  normal	  host	  cells	  can	   aid	   in	   generating	   a	   protective	   niche	   for	   melanoma	   cells	   undergoing	   BRAF	   inhibitor	  therapy.	  Combination	  therapies	  such	  as	  BRAF+PI3K	  inhibition	  may	  provide	  one	  strategy	  to	  block	  or	  limit	  microenvironment-­‐mediated	  adaptive	  therapy	  escape.	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claims arising out of your use of the licensed material other than as specifically authorized
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in this License at their sole discretion, for any reason or no reason, with a full refund payable
to you.  Notice of such denial will be made using the contact information provided by you. 
Failure to receive such notice will not alter or invalidate the denial.  In no event will Elsevier
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incurred by you as a result of a denial of your permission request, other than a refund of the
amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied
permissions.
LIMITED LICENSE
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unless your license was granted for translation rights. If you licensed translation rights you
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maintain the copyright information line on the bottom of each image; A hyper-text must be
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copyright information line on the bottom of each image.
Posting licensed content on Electronic reserve:  In addition to the above the following
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bona fide students registered on a relevant course. This permission is granted for 1 year only.
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For journal authors:  the following clauses are applicable in addition to the above:
Permission granted is limited to the author accepted manuscript version* of your paper.
*Accepted Author Manuscript (AAM) Definition: An accepted author manuscript (AAM)
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and which may include any author-incorporated changes suggested through the processes of
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 114 
	  
6/17/14 9:57 PMRightslink Printable License
Page 5 of 7https://s100.copyright.com/CustomerAdmin/PLF.jsp?ref=a9d34922-6efd-403b-ad9e-24c09594c102
enhancements and (if relevant) pagination.
You are not allowed to download and post the published journal article (whether PDF or
HTML, proof or final version), nor may you scan the printed edition to create an electronic
version. A hyper-text must be included to the Homepage of the journal from which you are
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published article and should be included in the posting of your personal version. We ask that
you wait until you receive this e-mail and have the DOI to do any posting.
Posting to a repository: Authors may post their AAM immediately to their employer’s
institutional repository for internal use only and may make their manuscript publically
available after the journal-specific embargo period has ended.
Please also refer to Elsevier's Article Posting Policy for further information.
18. For book authors the following clauses are applicable in addition to the above:  
Authors are permitted to place a brief summary of their work online only.. You are not
allowed to download and post the published electronic version of your chapter, nor may you
scan the printed edition to create an electronic version. Posting to a repository: Authors are
permitted to post a summary of their chapter only in their institution’s repository.
20. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be
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